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CHAPTER 1 INTRODUCTION
Nanoscaled materials are structures with a size of less than 200 nm, and
they show different physical and chemical properties compared with their
bulk correlatives. Application of Gold nanoparticles (AuNPs) has a long
history which can be tracked back to centuries B.C. by ancient scientists.(1)
AuNPs are particularly attractive in modern biomedical area due to their
versatile surface chemistry, ease of imaging, low toxicity, and engineerability
to take advantage of blood-brain barrier transport mechanisms.(2, 3) AuNPs
are being widely investigated for sensing, immunoassays, bioimaging for
diagnostics, targeted delivery of drugs, genetic materials, antigens, and
diagnostic agents.(4) For example, in combination with radiation, AuNPs
have proven successful at dissolving deposits of beta-Amyloid, the protein
involved in Alzheimer’s disease.(5-8) And as a result of the surface plasmon
resonance (SPR) effect, AuNPs can have a wide range of excitation upon
receiving wavelength from visible to infrared, which gives a great potential
of optical applications.(9)
This dissertation described a method of utilizing gold nanoparticles
(AuNPs) with various surface modifications in order to adapt various use in
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drug delivery systems. The main system involved is a tripartite
nanoconjugate consists of drug, targeting protein, and AuNP as vehicle, and
the nanoconjugate has been used to treat respiratory malfunction after
spinal cord injury and recovery has been obtained after a single
intramuscular injection. Besides, this dissertation also described using AuNPs
to increase solubility of drugs by conjugating the poorly-soluble drug with
AuNPs. The drug-conjugated AuNPs caused cell death and shrink of tumors
after administration. This dissertation also discussed the cytotoxicity of
AuNPs in biomedical applications. Different sized AuNPs has been tested
using human embryonic stem cells (hESCs), and the size-dependent toxicity
of AuNPs were observed and discussed.
In chapter 2, a literature review will be presented to show currently used
methods of AuNPs fabrication and modification based on different aspects
of applications. Then a detailed description of application of AuNPs in
biomedical area will be included, and the safety of AuNPs will also be
discussed.
Chapter 3 will focus on an engineered nanoconjugates aiming to bringing
recovery of respiratory after spinal cord injury in an established animal
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model. Various characterization methods were used to determine the
composition, size, shape, and stability of the nanoconjugates. And the
recovery of breathing was detected based on electromyography (EMG)
technique. Dosage optimization were also included in this chapter.
Chapter 4 describes an increase of solubility was introduced by
conjugating an anti-cancer drug with AuNPs through chemical bonding. The
nanoconjugate were injected locally and cell death were observed.
Chapter 5 describes a size-dependent toxicity study involving AuNPs with
core size of 1.5 nm, 4 nm, and 14 nm. All three types of AuNPs were modified
with surfactants to achieve better biocompatibility, but a considerable
toxicity was observed for 1.5 nm sized AuNPs when treating with hESCs. In
the meanwhile, AuNPs with size of 4 nm and 14 nm show no toxicity in this
study.
Chapter 6 concludes this work in gold nanoparticle engineering aiming to
obtain a biocompatible drug delivery system without introducing toxicity.
CHAPTER 2 LITERATURE REVIEW
2.1 Fabrication and functionalization of gold nanoparticles (AuNPs)
2.1.1 Synthesis of gold nanoparticles (AuNPs)
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With the reduction of gold chloride by phosphorus, Michael Faraday is
believed to be one of the first who reported the synthesis of stable gold
nanoparticle back in year 1857.(10) Today well established preparation
protocols have been developed for AuNPs with various size, shape, and
surface modification.(11) With ease of adjusting ratio between gold salt (for
example, HAuCl4), reducing agent, and capping/protecting agent, wet
chemical synthesis is mostly used to prepare AuNPs with diameters ranged
from ~2nm to 50nm.(12-15) Also, a cetyltrimethylammonium bromide
(CTAB)-assisted two-step method was raised by Murphy(16) and El-Sayed(17)
for gold nanorods synthesis, a seed solution with gold clusters in size of less
than 2nm is used in the first step followed by addition of surfactant CTAB.
Besides

simple

oxidation-reduction

based

chemical

methods,

photoreduction, electrochemical synthesis, and plasmon-driven synthesis
are also developed.(11) In the mind of “green chemistry”, Mukherjee, P., et
al.(18)reported that AuCl4- ions are reduced by the fungus Verticillium sp. to
obtain monodispersed AuNPs which was the first report the use of
eukaryotic organisms in AuNP biosynthesis.
2.1.2 Functionalization and characterization of AuNPs
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In the purpose of introducing both biocompatibility and intracellular
stability, proper surface functionalization is obviously necessary. Capping
ligands including but not limited to thiolates(19), dithiolates(20), amines(21),
and carboxylates(21) are all reported in preparation of AuNPs based on
different reaction mechanisms(22). Coupled with the binding, the shift of
surface plasmon resonance (SPR), change of redox activity, and change of
conductivity are observed, which can be used for clinical diagnosis and
biosensing.(23-25) By acting as “spacer” and “linker”, thiolated non-toxic
long chain polymers such as thiolated polyethylene glycol (PEG-SH) has been
used widely with the favor of strong Au-S bonds(26) and flexibility of
subsequent functionalization on the other end. However in order to fully
take advantage of the Au-S bonding: alkanethiolate-stabilized gold
nanoparticles are very stable in aqueous solution as well as organic solvent,
a lot efforts have been put in altering the structures of thiolates used to
stabilized the nanoparticle surface.(27-31) Besides, serum proteins, for
example, bovine serum albumin (BSA), are also proven effective in providing
good stability for nanoparticle dispersion in culture medium by forming
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protein corona.(32, 33) All the functionalization also contribute to decreasing
or/and avoiding toxicity of AuNPs when introduced into physiological models.
The surface modification can not only modify properties of AuNPs, fate
of small molecules within physiological environment would also be altered
after bonded with AuNPs. Such as CTAB, one of the normally used surfactant
in AuNP synthesis, which is cytotoxic while as free molecules, will become
nontoxic after binding to gold nanorods.(34) A more practical use of the
surface modification is engineering of therapeutic molecule delivery devices.
One recent example is that conjugating a small molecule inhibitor SMI#9,
which is specific designed for killing cancerous cells, with mercaptosuccinic
acid coated AuNPs results in a high therapeutic efficiency combined with
good selectivity.(35)
Nanoparticle properties and functionalization completeness can be
qualitatively tested by spectroscopy (e.g. IR, Raman, UV-Vis), electron
spectroscopy

(e.g.

TEM,

SEM),

dynamic

light

scattering

(DLS),

thermogravimetric analysis (TGA). However, the disadvantages of these
methods are not ignorable. TEM and SEM are having resolution problems
especially when experiment was conducted evolving cell samples and ultra-
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small sized AuNPs or gold nanocluster.(36) Because of the correlation model
it based on, DLS can only be used to measure relative pure spherical particles
with narrow size distribution.(37) TGA needs sample amount to be at least
1mg, which is considered a large amount in nano-scale study.
In order to quantify the composition of AuNPs, Rotello, et al.
suggested that with a combination of laser desorption/ionization (LDI) and
inductively coupled plasma (ICP) mass spectrometry both amount of
functional ligands and conjugate stability can be measured. (38) A
fluorescence-based method was developed which can be used to
quantitatively assess surface coverage and hybridization efficiency of gold
films.(39)
2.2 Applications of AuNPs in biomedical area
The application of AuNPs has been broaden widely with the
development of various detection techniques. This involves detection and
photothermolysis of cancer cells, biosensing of both microorganisms and
cells, optical imaging, X-ray enhancement, and targeted delivery of various
biomolecules. Among these applications AuNPs were used solely or after a
conjugation with different compounds.
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2.2.1 Photothermal and photodynamic therapy
Nanostructures have a higher accumulation among cancerous tissues
because of a disordered vessel structure and a porous membrane. This
enhanced permeability and retention(EPR) effect has been utilized for
passive delivery of nanoparticles for a long time.(40) AuNPs, upon absorption
of light with certain wavelength in visible and near-IR region, will heat up
rapidly, and as a result, this high temperature will kill the cells around or
containing AuNPs. This is the basic concept of photothermal therapy using
AuNPs.(41)
Using AuNPs in photothermal therapies is rising great interest
especially after combining with laser radiation which offers a better
penetration with a limited, controllable damage to cancer cells.(42) This is
proved to be promising for effective therapy towards chemotherapyresistant cancerous types.
Despite the heat created by the absorption of certain wavelength,
AuNPs will also undergo a different photochemical mechanism to generate
highly reactive radicals, which will also introduce necrosis and apoptosis in
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cells. This photodynamic method using AuNPs has been applied to
oncological diseases and skin diseases for decades.(43, 44)
The main problems for photonic therapies involving AuNPs are that 1)
the colloidal stability of the particles that are used in the methods, and 2) the
enhancement of delivery or accumulation of AuNPs in the targeted sites.(45)
But it is promising due to the favor of great tunability of AuNPs and the ease
of fabrication without using of certain compounds other than the particle
itself.
2.2.2 Bioimaging and visualization
Thanks to its high electron density as a heavy metal, gold nanoparticles
have a good resolution under transmission electron microscope (TEM) and
has been studied since 1970s.(46) High resolution TEM has been used to
determine the cellular uptake of AuNP and interactions between AuNP and
various biomolecules, microorganisms, and microstructures. However,
particularly in biomedical area, optical microscopy methods using AuNPs are
becoming more popular recent years.
After combining with label molecules such as fluorescent dye or
antibody, penetration and localization of nanoparticles can be monitored at
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a real-time style with confocal.(47-49) Especially, with its plasmonic property,
AuNP can enhance the contrast of target molecules or structures inside cells
result from the multi-photon resonance.(50-52)
AuNPs are also proved to have a higher magnitude comparing with
fluorescence under dark-field microscopy because of smaller scattering cross
section.(53) After conjugation with antibodies, AuNPs can only bind to
cancer cells through an antibody-antigen interaction solely between the
nanoconjugates and the cancerous cells, with dark-field microscopy this
specific binding can be seen and used to pinpoint cancer cell from normal
cell at a single-cell resolution.(54)
2.2.3 Delivery of targeted biomolecules
As described above, biomolecules can bind to AuNPs through both
chemical conjugation and the binding type can be tuned to be biodegradable
or biostable.(55) In most of the study, the biomolecules are anti-cancer
molecules, and are proved to be effective thanks to EPR effect.
Other than anti-cancer therapy, AuNP is also a potential candidate for
gene therapy after conjugation delivery of genetic materials.(56-59)
2.3 Challenges for drug delivery using AuNPs
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2.3.1 Colloidal stability
AuNPs easily aggregate when encountering with high-ionic-strength
environment, and in order to make it biocompatible, colloidal stability of
AuNPs should be carefully engineered, considering the physiological
condition involves high concentration of salts and a wide range of
biomolecules such as proteins and enzymes.
A standard method to guarantee dispersibility, uniformity, and
biocompatibility is to use surfactants to modify the surface of AuNPs.
Currently thiol compounds such as glutathione, mercaptopropionic acids,
cysteine, dihydrolipoic acid, thiolated polyethylene glycol, and their
derivatives are considered as the most biocompatible surfactants to be
applied to AuNPs.(60-63) The reason is that Au-S bond is more stable than
most of the other type of bond between the surface of AuNP and surfactant,
and the variability of the thiol compounds is offering possibility of further
modification depending on the demand of the conjugate. Even with a good
coverage of surfactant, after introduction of physiological condition, the
stability of AuNPs will still vary from case to case, and there has not been a

12

standardized investment of the colloidal stability of AuNPs in commonly
studied aqueous environment.
2.3.2 Nanotoxicity of AuNPs
As a well-established yet highly active area, AuNPs are being widely
used as imaging enhancer, therapeutic agents alone by themselves, and
engineered targeted delivery carriers for drugs, oligonucleotides, antigens,
and diagnostic agents.(4, 64-67) AuNP has also been used in consumer
market for decades considered non-toxic and inert same as its bulk
compartment. Both scientific research and marketing field have an urgent
need for systematic nanotoxicity assessment concerning influence of AuNPs
on human health.
Cytotoxicity assessment has been one of the most active area
considering the amount of various of products applied into market especially
those related with human health. In vitro assays haven been proven to be
commonly used due to ease of reproducing, refining, and replacing.(68, 69)
Here we briefly summarized several assays that are used in standard in vitro
toxicity evaluation experiments based on different mechanisms.
2.3.2.1 Cell growth inhibition

13

A very obvious and straightforward result after inducing analyte for
toxicity assessment is change of cell growth speed, and/or cell death. By
comparing cell counts between different treatments the influence of analyte
can be evaluated. Both live cells counting methods such as hemocytometry
and colorimetric assays are used. Well established assays such as the 3-(4,5dimethylthiazolyl-2)-2,5-dephenyltetrazolium bromide (MTT) based on the
reduction of tetrazolium dye by cellular mitochondrial dehydrogenase
present only in viable cells, the purple formazan product is soluble under
intracellular environment and is easy to be quantified by photometry. Similar
assays utilizing tetrazolium dyes such as XTT, MTS and the WST-1 are all
ready-to-use assays for cell viability and toxicity study via monitoring
enzymatic activity of mitochondrial.(70) Another method, sulforhodamine B
(SRB) assay, based on measuring cellular protein content can also provide
comparable sensitivity coupled good reproducibility.(71)
2.3.2.2 Membrane integrity lost
Toxicity inducing may also include membrane interfering which may
result in permeability change and compound leakage. Among dye exclusion
assays, trypan blue is commonly used which can only be uptaken by
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nonviable cells lacking membrane functions.(72) The blue color staining by
trypan blue can differentiate the viable cells from the dead and a subsequent
cell counting can evaluate the viability quantitatively.(72, 73) Another
reliable and simple assay is lactate dehydrogenase (LDH) leakage method.
The intracellular loss of LDH and resulting leakage is an indicator of
membrane dysfunction and measuring the activity of extracellular LDH can
be used to assess the status of cells.(74)
2.3.2.3 Metabolic activity decreasing
Cell metabolism can be also indicated by the concentration of either
Adenosine triphosphate (ATP) or certain protein. ATP is playing a role in all
metabolically activity inside cells. The bioluminescent assay can quantify ATP
concentration using luciferase.(75) Enzymes are important in regulation
gene expression, metabolic activity, and gene variation, such as Cytochrome
P450.(76) Both common enzyme-linked immunosorbent assay (ELISA) and
gel electrophoresis are used testing CYP450s.(76)
3.3.2.4 Epigenetic affects
How cells express genes are obviously important in cell viability, and
the change of gene expression is altered by epigenetic change.(77) Although
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epigenetic change is natural, it is also affected with inducing of certain toxic
materials such as gold nanoparticles.(36) Global DNA methylation status can
be determined by immunoprecipitation based colorimetric assays.(36)
Most of in vitro assays are using immortalized cell lines or mature cell
lines, this makes it difficult to correlate the results from cancerous cells or
animal cells to healthy, human cells. The specificity of targets needed for
each assay also increases its uncertainty when disruption of membrane
and/or mitochondria may be caused by the particle induced. On the other
hand, to avoid ethic issue and high expense, experimental cell lines and
animal models are preferred. For example, zebrafish has less than 1%
heterologous genes corresponded with early embryo development
compared with that of human, which makes it an ideal model in AuNP
cytotoxicity study.(78)
2.3.2.5 Toxicity dependence
While strategies for cytotoxicity and cell uptake study of AuNPs are
raised so differently between research labs, the dependence of toxicity is
well agreed. Surface charge dependent toxicity is quite straightforward that
positively charged AuNPs are more toxic due to the ease of disruption to the
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negatively charged cell membrane.(79) Meanwhile several different
mechanisms are postulated describing the size dependent cytotoxicity
caused by AuNPs based on various experiment models and designs both in
vitro and in vivo. (80-83)
First and one of the most common mechanism is intracellular reactive
oxidative species (ROS) induced by nanoparticles. Pan, et al. (81)showed that
triphenylphosphine monosulfonate (TPPMS)-capped AuNPs with a gold core
of diameter 1.4nm is superb toxic result in necrosis caused by oxidative stress
while 15nm-AuNPs of similar chemical composition are nontoxic.
Furthermore, reduced toxicity after pretreating cells with anti-oxidants (e.g.
glutathione) supported the ROS theory. Note that in the same study
important role of capping ligands has been high-lightened that glutathione
capped AuNPs with similar diameter (1.1nm) do not induce cell death.
However, a newly reported thiolate-coated gold nanocluster Au55 is highly
toxic when treating human embryonic stem cells (hESCs).(36) Second
mechanism states that cytotoxicity is due to the ultra-small size of Au55
clusters enables irreversible coordination between the clusters and the
major grooves of DNA molecule.(80) Among various cellular molecules, Au55
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clusters surprisingly bind to DNA molecules in a large fraction, which is
believed to affect transcription and/or duplication in the cell. This is due to
a) the dimensional fitting between gold clusters of ~1.4nm and major
grooves of DNA; b) the polydentate ligand system of nucleus provides higher
stability compared to the monodentate capping ligands.(80) Third
mechanism involves cell membrane interference. One study shows that Au55
clusters are extremely toxic to hESCs even after pretreatment with thiolate
capping ligands, and without evidence of entering the cells they concluded
that some disruptions towards cell membrane occurred.(36) Rotello group
believes that the toxicity is related with the strong electrostatic interaction
between the negatively charged bilayer with cationic ligand coated AuNPs,
which can be addressed by anionic capping.(79) Another group is attributing
the interference to blockage of membrane ion channels(84), note that in this
case after thiol-stabilization the toxicity is reduced.
AuNP cytotoxicity, especially caused by Au55 clusters, appears to be
capable of being reduced by modifying the AuNPs with proper capping
ligands such as thiolates.(81, 82) While the toxicity study is mainly conducted
in cell based experiments, in order to make the connection between in vitro
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models and vertebrate animal models, the extended fish embryo test (FET)
using zebrafish is applied.(83) In this study, toxicity of lethal
triphenylphosphine monosulfonate (TPPMS) capped 1.4 nm AuNPs was
reduced largely after addition of glutathione, which is due to replacement of
capping ligand on the AuNP surface. Note that in the same study it also shows
different toxicity compared with HeLa cells study conducted by the same
group.(83)
However, there are some exceptions which are of great interest. As
described above, a large number of toxicological studies are in vitro methods
using immortalized cell lines, which may not provide information concerning
biological barrier penetration, organ and/or cell specificity, embryonic
development and subsequent differentiation. Another issue is that animal
studies conducted using either zebrafish model or small rodent model make
it hard to compare with human body. Instead of using cancerous cell lines,
mouse embryonic stem cells are used to assess embryotoxicity in several
experiments (85, 86), even more, a research of first use of human embryonic
stem cells (hESCs) for embryotoxicity and neurotoxicity test has been
reported.(36) hESCs is very suitable for cytotoxicity not only because it is a
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normal cell lines, but also because of its pluripotency makes it extremely
important to help determine the effects of AuNPs on differentiation process
as well as on the differentiated neural progenitor cells (NPCs). Sizedependent cytotoxicity was observed when inducing AuNPs in 1.5nm, 4nm,
and 14nm with coating of thiolate capping ligands, 1.5nm AuNPs is extremely
toxic and killed most of the hESCs while 4nm- and 14nm-AuNPs showed
nontoxic.(36) In the same study it also shows that when exposed to all three
sizes of AuNPs under nontoxic dosage the in vitro differentiation potential
would not be affected, however, during neural differentiation, 1.5nmAuNPstreated group showed smaller embryo bodies which suggested that AuNPs
in this size may cause negative influence even at sublethal concentration.
After inducing 1.5nm AuNPs, NPCs were almost dead after 3 days referring
to further toxicity of small size AuNPs. Note that cell uptake analysis shows
that AuNPs in 1.5nm cannot enter hESCs in a noticeable amount instead a
large amount of accumulation in the feeder layer cells was found.(36) This
indicates that uptake of AuNPs varies among different cell lines, and this
difference may lead to different toxicity mechanisms.
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CHAPTER 3 ENGINEERING OF GOLD NANOPARTICLES CAPABLE OF
BYPASSING BLOOD-BRAIN BARRIER
This chapter is reproduced with permission from the Scientific
reports 6 (2016): 25794. Yanhua Zhang, Janelle Buttry Walker, Zeljka Minic,
Fangchao Liu, Harry Goshgarian, and Guangzhao Mao. "Transporter protein
and drug-conjugated gold nanoparticles capable of bypassing the bloodbrain barrier." And the Journal of Spinal Cord Medicine, accepted on 3th
January 2019. Fangchao Liu, Yanhua Zhang, Janelle L. Buttry Walker,
Guangzhao Mao, and Harry G. Goshgarian. " Diaphragmatic Recovery in
Rats with Cervical Spinal Cord Injury Induced by a Theophylline
Nanoconjugate: Challenges for Clinical Use".
3.1 Introduction
The leading causes of death among persons with spinal cord injury (SCI)
since 1973, according to the National SCI Database, are from pneumonia and
septicemia due to damage to respiratory muscle function caused by SCI(87).
The major therapeutic challenge in the treatment of respiratory dysfunction
caused by SCI, similar to other neurological diseases, is the inability of many
drugs to go across the blood-brain barrier (BBB). The BBB is a natural defense
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system for the brain and generally only permits diffusion of neutral, lipophilic,
and low molecular weight (smaller than 400-600 Da) molecules into the
central neuron system (CNS) from blood(88, 89). Wheat germ agglutinin
(WGA) is a lectin recognized by N-acetylglucosamine and sialic acid located
on most neuronal cell membranes(90, 91) . WGA, in a few studies, has been
used to enhance intranasal delivery of peptides to the brain through the
olfactory route due to its affinity to the olfactory mucosa(92, 93). However,
to our knowledge, this is the first study to use wheat germ agglutininhorseradish peroxidase (WGA-HRP) as a targeting moiety to transport drugbound nanoconjugates of tens of nanometers in size exclusively to the
phrenic motoneurons that control respiratory function, effectively bypassing
the BBB. When injected into muscle, WGA bound conjugates undergo
retrograde transport to the motoneuron cell bodies and is then
transsynaptically transported to the pre-motor neurons(94, 95). We
synthesized a three-part nanoconjugate consisting of WGA-HRP chemically
bound to AuNPs, which were also chemically bound to drugs previously
shown to induce recovery of the diaphragm paralyzed by SCI. Following
intramuscular injection into the diaphragm, the WGA-HRP component of the
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nanoconjugate engages in receptor-mediated endocytosis resulting in
retrograde transport of the nanoconjugate within motoneurons to the
phrenic nuclei in the cervical spinal cord and transsynaptically to the rostral
ventral respiratory groups (rVRGs) in the medulla. The drug, 1,3dimethylxanthine (theophylline or THP), is an adenosine receptor antagonist
clinically used for the treatment of respiratory dysfunctions such as asthma,
bronchitis, and respiratory muscle paralysis resulted from SCI(96-98). In rats
with a spinal cord hemisection at the second cervical spinal segment (C2Hx),
systemic (oral or intravenous) administration of THP or another adenosine
receptor antagonist, 1,3-dipropyl-8-cyclopentylxanthine (DPCPX), resulted
in an increase in respiratory output and recovery of the respiratory related
activity by stimulating the crossed phrenic pathway (CPP)(97, 98). The CPP is
a latent pathway, which crosses the midline below the level of SCI injury to
synapse on the ipsilateral phrenic nuclei (PN) in the 3rd through 6th segments
of the cervical spinal cord while the primary descending pathway, between
the neuronal connection from the rVRG in the medulla to the ipsilateral
phrenic nucleus, has been severed by a high cervical SCI(94). However, in
humans the therapeutic dose of methylxanthines causes intolerable side
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effects including nausea and seizures(99, 100). These side effects are
associated with nonspecific biodistribution and neuronal hyperactivity
induced by the drug. Therefore, we designed a nanoconjugate in which the
drug and the transporter protein are chemically linked through a
nanoparticle carrier, the AuNPs, in order to reduce side effects of the drug
by delivering it selectively to the respiratory neurons in the cervical spinal
cord and medulla. A biodegradable bond between the drug and the
nanoparticle carrier enables drug release at the targeted sites. The
effectiveness of the nanoconjugate drug delivery was verified by the return
of diaphragm muscle function previously paralyzed due to SCI. AuNPs were
selected as the drug carrier due to their biocompatibility, tunable colloidal
chemistry, and quality control through a wide range of analytical
methods(101, 102).
3.2 Experimental methods
3.2.1 Materials
Chemicals used in the following experiments: gold(III) chloride
trihydrate (HAuCl4∙3H2O, 99% metal trace); sodium citrate tribasic dehydrate
(98%); mercaptosuccinic acid (MSA, 97%); sodium borohydride (NaBH4, 98%);
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4-dimethylaminopyridine (DMAP, 99%); dimethyl sulfoxide (DMSO, 99.8%);
37%

formaldehyde

solution;

tetrahydrofuran

(THF,

99%);

N-

hydroxysuccinimide (NHS, 98%); dipropylcyclopentylxanthine (DPCPX, 97%);
theophylline (THP, 97%) triethylamine (Et3N, 99%); lectin from triticum
vulgaris

(WGA-HRP)

(Sigma-Aldrich,

St.

Louis,

MO);

1-Ethyl-3-(3-

dimethylaminopropyl) carbodiimide (EDC, 98%) (Sigma-Aldrich, St. Louis,
MO).
3.2.2 Nanoconjugate Synthesis and characterization
The detailed synthesis of the nanoconjugate (WGA-HRP-AuNP-proTHP)
has been published elsewhere (103). Briefly, to link theophylline to the AuNP
via an ester bond, a hydroxymethyl group was added to theophylline creating
7-(hydroxymethyl) theophylline or “proTHP”, using the Mannich reaction
(103, 104). The reaction product was analyzed by proton nuclear magnetic
resonance (1H NMR) to verify the formation of proTHP. Gold chloride (HAuCl4)
was reacted with tri-sodium citrate to synthesize AuNPs. Mercaptosuccinic
acid (MSA) was added as the capping ligand for the AuNPs. Then proTHP was
attached to the MSA-capped AuNPs via a biodegradable ester bond to enable
in vivo drug release (105). WGA-HRP was coupled to the MSA-capped AuNPs
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via an amide bond (106). Each step of the synthesis was verified by UV-vis
spectroscopy, transmission electron microscopy, dynamic light scattering,
and thermogravimetric analysis (TGA). Due to the instability of the
synthesized proTHP, proTHP was stored in argon to prevent hydrolysis of the
hydroxymethyl group by moisture in room air. In addition, to limit variation
due to the biodegradable nature of the ester bond linking the AuNP to 7(hydroxymethyl) theophylline, the final solutions were only used up to 30
days after synthesis.
A variation of the nanoconjugate synthesized with hydroxyethyl
theophylline (Sigma-Aldrich) in place of the 7-(hydroxymethyl) theophylline
was also produced. The hydroxyethyl theophylline variation was tested to
determine if the ester bond between theophylline and AuNPs could be
further stabilized.
UV-vis absorption spectroscopy (Varian Cary 50) was used to
determine the AuNP size based on the Beer-Lambert law. The scan range was
200–800 nm.
The transmission electron microscope (TEM) images were taken on a
JEOL JEM-2010 electron microscope. Samples were prepared by placing a
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droplet of the nanoconjugate solution on a Formvar-coated copper TEM grid.
Excess liquid was removed by filter paper under the grid and the sample was
air-dried. The working voltage was 200 keV and the current was 109 mA. For
each image, 30 particles were randomly selected and measured to give the
nanoparticle size distributions.
The nanoparticle size was determined by dynamic light scattering (DLS)
(Zetasizer Nano ZS, Malvern). A one ml solution of nanoparticle in PBS buffer
was placed in a 2.0 ml polystyrene cuvette. The backscattering angle Θ was
fixed at 180° with a laser wavelength λ = 633 nm. The size measurement
range was set between 1 nm and 6 μm. The electrophoretic mobility of the
nanoparticles was measured using the laser Doppler velocimetry and phase
analysis light scattering technique of the Malvern Zetasizer. The
electrophoretic mobility was converted into a zeta potential using the
Smoluchowski equation using the Malvern software.
TGA analysis was used to quantify the chemical composition of the
nanoconjugate. TGA was performed on the SDT-Q-600 instrument using air
as the working gas. The temperature range was 100–800 °C with a heating
rate of 10 °C/min.
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The LDI-MS measurements were carried out on a Bruker
UltrafleXtreme MALDI-TOF/TOF Mass Spectrometer (Lumigen Instrument
Center, Detroit). The samples were analyzed by LDI-MS after being
transferred onto a MALDI target for LDI-MS analysis without adding any
organic matrix. All mass spectra were acquired in the reflection mode and
represent an average of 500 laser shots at a repetition frequency at 500 Hz.
The accelerating voltage was set to 20 kV. The laser power was optimized in
the range of 70–90% for each sample. The Bruker software flexAnalysis
(version 3.4) was used for data analysis. Each sample was measured 10 times
by LDI-MS.
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Figure 3-1 Synthesis schematic of transporter protein WGA-HRP and drug
THP conjugated to the AuNPs.
3.2.3 C2 Hemisection Surgery
All animal studies were approved by the Wayne State University
School of Medicine Institutional Animal Care and Use Committee. In addition,
all experiments were carried out in accordance with the Code of Ethics of the
World Medical Association for experiments involving animals. Adult male
Sprague Dawley rats were used in these studies (N=123). The rats were
injected with atropine sulfate (0.04 mg/kg, im) 10 min prior to anesthesia
induction to reduce mucus secretions during the subsequent aseptic survival
surgery. The initial dose of anesthesia was a mixture of ketamine (70 mg/kg,
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ip) and xylazine (7 mg/kg, ip). After anesthesia induction, bupivacaine (2
mg/kg, sc), a local anesthetic, was injected into the dorsal neck. The neck was
then shaved and prepared for aseptic surgery. A left C2Hx surgical procedure
was carried out as previously described (94). The dorsal neck muscles were
closed using 4–0 absorbable sutures (Vicryl) followed by wound clips (Reflex®
9 mm) for the skin.
3.2.4 Electromyography (EMG) Analysis
In all rats, immediately after C2Hx, paralysis of the ipsilateral
hemidiaphragm was confirmed by EMG analysis. The previous study by
Moreno and colleagues (94) correlated the loss of EMG activity in the
ipsilateral hemidiaphragm to the lesion extent damaging the ipsilateral
lateral and ventral funiculi of the cervical spinal cord where the descending
respiratory drive is located, which was used here to ensure a complete
hemisection (94). The abdominal surface of the diaphragm was exposed by
a 6–8 cm horizontal incision made approximately 0.5 cm caudal and parallel
to the costal margin. Bipolar platinum wire electrodes (Grass F-E2) were
placed in each side of the diaphragm. Signals were amplified (20,000×) and
band pass-filtered (30 Hz–3 kHz) by Grass amplifiers (model P511 AC, Astro-
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Med, Inc., West Warwick, RI) and raw EMG signals were recorded by a
Cambridge Electronic Design (CED, Cambridge, England) data acquisition
system integrated with CED Spike 2® software. Recordings were taken from
three areas of the left hemidiaphragm: anterior (sternal), lateral (costal) and
posterior (crural). C2Hx rats that showed a complete absence of activity in
all three areas and could produce an augmented breath were included in the
study. An augmented breath is a confirmation that the CPP is intact and
functional (94, 107).
To observe the course of effect of theophylline following
nanoconjugate injection subsequent EMGs were sampled from day 2 post
injection up to and including day 14. Each rat underwent at minimum 1 EMG
and no more than 3 separate EMGs with a minimum of 1 day between
surgeries. The days selected for EMG were determined based on the time
course for each rat and how many surgeries had already occurred; days 2
through 7 each had a minimum of 7 rats used for data on each day.
Subsequent EMG recordings were performed under ketamine/xylazine
anesthesia while spontaneously breathing.
3.2.5 Nanoconjugate Administration
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Following EMG confirmation of hemidiaphragm paralysis immediately
after the C2Hx, intradiaphragmatic injections were administered. Groups
received injections based on their weight of one of the following solutions; i)
nanoconjugate

(WGA-HRP-AuNP-proTHP)

0.0005

mg/kg

N=3,

ii)

nanoconjugate 0.0008 mg/kg N=4, iii) nanoconjugate 0.0025 mg/kg N=4, iv)
nanoconjugate 0.005 mg/kg N=7, v) nanoconjugate 0.0075 mg/kg N=7, vi)
nanoconjugate 0.01 mg/kg N=6, vii) nanoconjugate 0.03 mg/kg N=19, viii)
nanoconjugate 0.07 mg/kg N=25, ix) nanoconjugate 0.12 mg/kg N=23, x)
WGA-HRP-AuNP N=6, xi) AuNP-proTHP 0.07 mg/kg N=8. Investigation of the
hydroxyethyl theophylline nanoconjugate consisted of 2 groups; 0.002
mg/kg N=5, and 0.3 mg/kg N=6. Injections (10µl maximum volume per
injection site) were spread equally from the posterior to anterior areas of the
diaphragm using a Hamilton syringe. The needle was inserted parallel to the
muscle fibers such that the tip of the needle was visualized by eye before
administration of the injections, the needle was held in place for 5–10
seconds before it was slowly withdrawn from the muscle to prevent
leakage(108).
3.2.6 Post Procedure Care
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Incisions were cleaned and the rats were given yohimbine (2mg/kg, ip)
to reverse the xylazine, and buprenorphine (0.01mg/kg, sc) in 10mL saline
for pain management. The rats were recovered on a heating blanket in a
supine position to limit pressure on the diaphragm. Once rats could
ambulate, they were returned to clean soft litter-lined cages with food and
water provided ad libitum on the floor of the cage. The rats were also given
cereal (Fruit-Loops®) as an enticement to eat. For the following 48-hours
post-operative period, injections of buprenorphine (0.01mg/kg, sc) were
given every 8-12 hours for pain management. Rats survived for 3, 7, or 14
days’ post injection depending on the timeline for each experimental group.
3.2.7 Immunohistochemical Visualization of Nanoconjugate
72 hours after intradiaphragmatic injection of the nanoconjugate
0.12mg/kg (N=3) into the left hemidiaphragm, rats were euthanized and
underwent transcranial perfusion using heparinized saline followed by 4%
formaldehyde (Fisher, F-79) (108). The cervical spinal cord (C3-C6) and
medulla were removed and post fixed in 4% formaldehyde for 24 hours
followed by 72 hours in 30% sucrose for cryoprotection. Tissues sections 50
microns thick were cut transversely on the cryostat and collected in PBS.
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Tissue sections containing the phrenic nuclei and rVRGs underwent the
immunohistochemistry protocol as described by Minic et al. (108); sections
were washed three times in the immuno-buffer (PBS with 0.3% Triton) and
then blocked using 10% normal horse serum (Invitrogen) in the immunobuffer. Sections were incubated in primary antibody goat anti-WGA (1:200,
AS-2024, Vector Laboratories), diluted in 10% normal horse serum immunobuffer solution for 72 h, and then washed in PBS. Sections were then
incubated in the biotinylated secondary antibody, donkey anti-goat
overnight (1:400, Jackson Immuno Research Laboratories). Sections were
then incubated in streptavidin-tagged-Cy3 for 4 h and then mounted wet on
the slides and coverslip. Tissue sections were examined on a Zeiss
Axioimager.M2 fluorescent microscope. Images were captured using the Zen
2 pro Blue edition program. Off-line processing was used to acquire highpower views of the phrenic nuclei and the rVRGs.
3.2.8 Phrenic Nerve Recordings
Bilateral phrenic nerve recordings were sampled at day 3, 7, and 14
under standardized conditions. The rats were injected with atropine sulfate
(0.06mg/kg, im) 10 minutes prior to anesthesia induction to reduce mucus
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secretions during the procedure. The anesthesia was a mixture of ketamine
(70mg/kg, ip) and xylazine (7mg/kg, ip), a supplement was provided as
needed. Phrenic nerves were accessed from the ventral surface of the neck
and cut distally to eliminate afferent activity. Each nerve was positioned on
platinum bipolar electrodes and coated with mineral oil to prevent fluid
interference with the signal and to reduce electrical noise. Before acquiring
nerve activity data, the following standardizing conditions were performed:
(1) animals were bilaterally vagotomized; (2) animals were paralyzed using
pancuronium bromide (0.5 mg/kg, iv); and (3) animals were placed on a
ventilator set at 3–5mmHg above the apnea threshold (108). The procedure
for determining the apnea threshold has been described previously (109).
The unprocessed recording was amplified 5000 times using Grass P511
amplifiers (Grass Technologies), filtered at 0.3–1 kHz. The recordings were
digitized, rectified, and integrated in 0.1 s intervals using the Cambridge
Electronic Design data acquisition system and the Spike 2 software.
3.2.9 Statistical Analysis
As described by Minic et al. (108), EMG analysis was intended to only
analyze the incidence of recovery not to determine the amount of recovery.
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Treatment groups were divided into a “Yes” or “No” category based on the
following criteria described by Minic et al. (108); Recovery of the left
hemidiaphragm was considered positive/Yes in each rat only if the following
conditions were met: (1) the EMG activity was detected in at least two of the
three diaphragm areas (posterior, lateral, or anterior); and (2) if the activity
persisted for the duration of the study. In each treatment group, rats were
then divided into those having recovery or not, and the Fisher exact test was
performed to determine whether the proportion of rats with an incidence of
recovery in the treated groups was statistically different from the ratio of
control animals with an incidence of recovery. The Fisher’s exact test was
followed by the Bonferonni adjustment to correct for the number of
comparisons tested. A α level of 0.016 was considered statistically significant
(SigmaPlot 13.0). Groups that demonstrated a significantly higher incidence
of recovery during the initial screening process, to determine optimal drug
dose, were further investigated using phrenic nerve recordings to quantify
recovery observed.
Terminal bilateral phrenic nerve recordings were used to estimate the
increase in phrenic nerve output after nanoconjugate injections as described
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by Minic et al. (108). The areas under 10 consecutive integrated waveforms
(INT) in the right phrenic nerve (RPN) and left phrenic nerve (LPN) activity
were averaged and expressed as mean ±SE. Activity of the LPN was used as
an index of the recovered respiratory activity in the THP nanoconjugatetreated rats. Both maximum (MAX) LPN amplitude activities as well as the
areas under the curves (AUC) were expressed as the percentage of the RPN
whose signal was set to be 100%. Then the average % INT and the average %
MAX for each group was averaged and subjected to statistical examination
using SigmaPlot 13.0. All groups underwent One-way ANOVA followed by
Holm-Sidak pairwise comparison to determine the effect of the injected
solution. A α level of 0.05 was considered statistically significant.
3.3 Results
3.3.1 Characterizations of AuNP conjugates
The nanoconjugates from each stage of synthesis were characterized
by UV-vis spectroscopy, transmission electron microscopy (TEM), dynamic
light scattering (DLS), and thermogravimetric analysis (TGA). Figure 3.2A
shows the UV-vis spectra of MSA-capped AuNP, AuNP-pro-THP, and WGAHRP-AuNP-pro-THP obtained in deionized water (pH = 5.8) at room
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temperature. The UV-vis spectra of a constant absorption peak at 508-510
nm are in the expected range for AuNPs with 4 nm core diameter and they
also indicate a high degree of colloidal dispersion stability at all stages of the
synthesis. Figure 3.2B-D show TEM images of MSA-capped AuNPs, AuNPpro-THP, and WGA-HRP-AuNP-pro-THP. The particle size histograms of
which are shown in Figure 3.2E-G, respectively. The AuNPs were well
dispersed and the diameter of the AuNPs remained unchanged at 4.1 ± 0.3
nm before and after conjugation with pro-THP according to TEM. The AuNPs
size increased slightly to 5.2 ± 1.3 nm. Here, there is uncertainty in particle
core size determination due to the conjugated WGA-HRP and overlapping
particles. Particle agglomeration, observed in WGA-HRP-AuNP-pro-THP
samples, is likely caused by the TEM sample preparation step (Figure 3.2C).

38

Figure 3-2 Characterization of transporter protein and drug-conjugated
AuNPs. A) UV-vis spectra measured at room temperature. B-D) TEM images
of AuNP conjugates. E-G) Sized distributions of AuNP conjugates
The zetasizer provided measurements of the particle hydrodynamic
size by DLS and the zeta potential by electrophoresis. The hydrodynamic
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diameters are 4.8 nm (zeta potential = -28.5 mV) for MSA-capped AuNP, 11.7
nm (zeta potential = -36.6 mV) for AuNP-pro-THP, and 37.8 nm (zeta
potential = -35.6 mV) for WGA-HRP-AuNP-pro-THP. The zeta potential
measurements were conducted in PBS buffer (pH = 7.4) at 37C. The
hydrodynamic size of different nanoconjugates are shown in Figure 3.3. The
size increase after each conjugation reaction is consistent of successful
coupling of the drug or protein to the AuNP. The negative surface charge
characteristic of all the nanoparticles provides the necessary electrostatic
repulsion to ensure aqueous dispersion stability of the nanoparticles.

Figure 3-3 Zetasizer measurements of A) pro-THP nanoconjugates and B)
pro-DPCPX nanoconjugates. All samples were measured in PBS buffer
(pH=7.4) at 37°C.
The

chemical compositions of the

intermediate and final

nanoconjugates were analyzed by TGA (Figure 3.4A). Based on the
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percentages of weight losses at different stages of synthesis, we were able
to estimate that in the final nanoconjugate, there are 204 pro-THP molecules
conjugated to one 4 nm MSA-capped AuNP and 2 MSA-capped AuNPs
conjugated to one WGA-HRP. The numbers of drug molecules conjugated
correspond to 60% occupation for pro-THP of all available carboxyl provided
by MSA. The detailed calculations can be found in the SI 1.3. We observed
that the number of conjugated drug molecules remained unchanged with
increasing drug to Au molar feed ratio in the reaction indicating that a
surface saturation was reached possibly due to a steric effect. It is interesting
to note that in both THP (Figure 3.4A) and DPCPX (Figure 3.4B) cases we
obtained similar protein to AuNP molar ratio of 1 to 2. This nanostructure
configuration is consistent with the TEM and DLS results.
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Figure 3-4 TGA data of weight loss for A)MSA-AuNPs, AuNP-pro-THP, and
WGA-HRP-AuNP-pro-THP; B) MSA-AuNPs, AuNP-proDPCPX, and WGA-HRPAuNP-pro-DPCPX.

Calculations of nanoconjugate drug and protein loading amounts
based on TGA and TEM results are shown below.
The weight of one molar AuNP (W) with a diameter (D = 4 nm based
on the TEM measurements) was estimated using the following formula using
the bulk density of gold ( = 19.3 g/cm3):

(

)

3
g
1
1
W =   D 3  6.022  10 23 = 19.3 3   4  10 −7 cm  6.022  10 23 = 3.89  10 5 g / mol
6
cm 6
.

The molecular weight of MSA (C4H6O4S) and pro-THP are 150 g/mol
and 210 g/mol, respectively. The weight loss, 100:6.6 = AuNP:MSA,
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corresponds to 171 MSA molecules per AuNP as calculated below. As a result,
each MSA-AuNP has 342 maximum reactive sites.
No. of MSA molecules =

6.6 3.89 10 5

= 171.16
150
100
.

The area of MSA coverage on AuNP (A) is calculated below:
A=

D 2
No. of MSA molecules

=

 (4nm )2
171.16

2
= 0.294 nm 2 = 29.4

.

The weight loss of 15.0% (AuNP: MSA: pro-THP = 100: 6.6: 11.1) shows
that 205.6 pro-THP molecules are conjugated to one AuNP as calculated
below:
No. of pro - THP molecules =

11.1 3.89  10 5

= 205.6
210
100
.

This means that 60% of all possible reactive sites provided by MSA are
occupied by pro-THP.
The total weight loss for the three-part nanoconjugate is 21.6% (AuNP:
MSA: pro-THP: WGA-HRP = 100: 6.6: 11.1: 11.5) indicates that each WGAHRP is conjugated to 2 AuNPs as calculated below:
11.5 3.89  10 5
No. of WGA - HRP molecules =

2
22367
100
.
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For pro-DPCPX drug (TGA spectra shown in Supplementary Fig. 3), the
weight loss of 12.9% (AuNP: MSA: pro-DPCPX = 100: 6.6: 8.2) corresponds to
96 pro-DPCPX molecules conjugated to one MSA-capped AuNP. This means
that 28% of MSA reactive sites are occupied by pro-DPCPX as calculated
below:
No. of pro - DPCPX molecules =

8.2 3.89 10 5

= 96
332
100
.

The total weight loss for the three-part nanoconjugate is 21.0% (AuNP: MSA:
pro-DPCPX: WGA-HRP = 100: 6.6: 8.2: 11.8) indicates that each WGA-HRP is
conjugated to 2 AuNPs as calculated below:
No. of WGA - HRP molecules =

11.8 3.89  10 5

2
22367
100
.

3.3.2 Immunostaining
Three

rats

underwent

intradiaphragmatic

injections

of the

nanoconjugate following a C2Hx to visualize the locations of the
nanoconjugate. An immunohistochemical technique was utilized to visualize
the WGA component of the nanoconjugate. The WGA-HRP-AuNP bond is a
relatively long-lasting amide bond whereas the AuNP-proTHP bond is a
transient ester bond. Therefore, we can assume that the location of WGA
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should also identify where the AuNPs are but not necessarily the proTHP. All
3 rats produced identical results verifying what was reported in (103). WGA
positive label was identified in the ipsilateral PN in the cervical spinal cord
and bilaterally in the rVRGs in the medulla (Figure 3.5). The bilateral rVRGs
labeling was notably less intense compared to the label in the PN. These
results suggest that at minimum, the WGA-HRP-AuNP portion of the
nanoconjugate is capable of being transported to the PN and subsequently
transsynaptically to the rVRG following intradiaphragmatic injection.
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Figure 3-5 WGA identified in the phrenic nuclei in the cervical spinal cord
and rostral ventral respiratory groups in the medulla 72 hours after
intradiaphragmatic injection. Scale bar is 50 μm. P (in A and E) notes
pinhole to mark side contralateral to the injection.

3.3.3 Electromyography (EMG)
Based on the criteria described by Minic et al. (108), results from EMG
analysis were used as a Yes/No screening tool to determine which doses
should undergo further analysis using the phrenic nerve recording technique.
Starting with the lowest tested dose, functional recovery of the diaphragm
after a one-time injection of the nanoconjugate dose 0.0005mg/kg was
detected in 66% of the rats (N=3). Diaphragm activity was detected as early
as day 3 and persisted to day 14, the longest time point tested. However, the
duration of the burst was less than the non-injured side. Therefore, in each
subsequent group, the dose was incrementally increased to find an optimal
therapeutic dose.
The doses 0.0008mg/kg and 0.0025mg/kg both resulted in a return of
diaphragm activity that occurred in 50% of the rats (N=4 and N=4,
respectively). Both doses resulted in diaphragm recovery lasting the full 14
days. The doses of 0.005mg/kg and 0.0075mg/kg resulted in the incidence of
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recovery in only 0.14% of the rats (N=7 and N=7, respectively) and the dose
0.01mg/kg resulted in no observable recovery (N=6).
When the dose was increased to 0.03mg/kg recovery was observed in
63% of the rats (N=19). Similarly, the dose 0.07mg/kg, resulted in the
incidence of recovery as early as day 2 post nanoconjugate injection and
lasted up to day 14 in 56% of the rats (N=25) (Figure 3.6), and the 0.12mg/kg
dose resulted in the incidence of recovery in 45% of the rats (N=20).
Interestingly, in 3 rats from the 0.12mg/kg dose group the LHD burst
frequency was minimal but sporadic and sometimes off rhythm compared to
the right side, a possible effect of over stimulation (97). Thus, we did not go
beyond the 0.12mg/kg dose in this study.
Injection of a control solution containing a conjugate of just AuNPproTHP 0.07mg/kg (no WGA-HRP) (N=8), or WGA-HRP-AuNP (no proTHP)
(N=6) never produced recovery of the LHD.
Investigation of the hydroxyethyl theophylline nanoconjugate
consisted of 2 groups; 0.002 mg/kg N=5, and 0.3 mg/kg N=6. The group that
received 0.002mg/kg never produced recovery of the LHD. The group that
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received 0.3 mg/kg had a 33% occurrence of recovery, however the bursting
patterns were sporadic in respect to the pattern produced by the RHD.

Figure 3-6 EMG traces 2 days and 14 days post injection 0.7 mg/kg
nanoconjugate. Both recordings were obtained from the same rat. A) 2 days
post injection of the dose 0.07mg/kg nanoconjugate there is a return of the
bursting pattern in the left hemidiaphragm (top trace). The bursts in the left
hemidiaphragm match those in the right hemidiaphragm (bottom trace). B)
14 days post injection; the activity has persisted in the left hemidiaphragm
(top trace) and remains synchronous with the right hemidiaphragm (bottom
trace). In both traces an augmented breath is demonstrated (arrows)
followed by a short period of apnea. The augmented breath shows the
crossed phrenic pathway is functional.
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Statistical significance of the incidence of functional recovery detected
with the EMG analysis was determined using the Chi Square-Fisher’s exact
test followed by the Bonferroni adjustment (Figure 3.7). Treatment with
0.03mg/kg, 0.07mg/kg, or

0.12mg/kg

of the

nanoconjugate

via

intradiaphragmatic injection resulted in a significantly greater proportion of
rats achieving functional recovery when compared to the control 0.07mg/kg
AuNP-proTHP; p=0.003, p= 0.010, p=0.029 respectively. Treatment with
0.03mg/kg or 0.07mg/kg of the nanoconjugate resulted in a significantly
greater proportion of rats achieving functional recovery when compared to
the dose 0.01mg/kg; p=0.015, p=0.021 respectively. In addition, treatment
with 0.03mg/kg or 0.07mg/kg of the nanoconjugate resulted in a significantly
greater proportion of rats achieving functional recovery when compared to
the control WGA-HRP-AuNP; p=0.015, p=0.021 respectively. However, with
lone EMG data it is unclear as to whether this is isolated muscle activity
stimulated by the injection containing proTHP (110-115), or if it is a return of
function mediated by the bulbospinal pathway via the phrenic nerve.
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Figure 3-7 Percent of Rats with EMG Recovery of the Left Hemidiaphragm.
The chart displays the percentage of rats in each group that had an incidence
of recovery detected by EMG of the left hemidiaphragm. Statistical analysis
consisted of data from 112 rats. A Chi-square test was performed, and
significance was found between the proportions of observations (Yes/No)
and the groups, X2 (13, N = 112) = 27.075, p = 0.012. Treatment with the
0.03mg/kg nanoconjugate resulted in significantly greater (#) incidence of
recovery compared to 0.01mg/kg (P = 0.015); WGA-HRP-AuNP (P = 0.015);
and 0.07mg/kg AuNP-proTHP (P=0.003). Treatment with the 0.07mg/kg
nanoconjugate resulted in significantly greater (†) incidence of recovery
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compared to 0.01mg/kg (P = 0.021); WGA-HRP-AuNP (P = 0.021); and
0.07mg/kg AuNP-proTHP (P = 0.010). Treatment with the 0.12mg/kg
nanoconjugate resulted in significantly greater (‡) incidence of recovery
compared to 0.07mg/kg AuNP-proTHP (P = 0.029).

3.3.4 Phrenic nerve recordings
Based on the screening data obtained from the EMG analysis the doses
0.03, .0.7, and 0.12mg/kg were selected to analyze the amount of recovery
based on the output of the phrenic nerves at days 3, 7, and 14. A
representative recording from each day. The nanoconjugate induced
recovery was quantified by analyzing 10 consecutive breaths from bilateral
phrenic nerve recordings sampled at days 3, 7, and 14. Controls solutions
were sampled on day 7. The area under the curve (AUC) from the right and
left integrated (INT) waveforms were calculated and the percent recovery of
the left compared to the right was calculated for both the INT and maximal
amplitude (MAX). The data used in the following statistical analysis was
obtained once physiologically standardized conditions were established (108,
109, 116-119). One-way ANOVA with Holm-Sidak pairwise comparison was
performed to determine the effect of the nanoconjugate or control solution
on the amount of left phrenic nerve (LPN) recovery.
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One-way ANOVA showed a significant drug effect on day 3 between
the 0.12mg/kg dose and the remaining two groups, 0.03mg/kg dose and
0.07mg/kg dose for the AUC (p<0.001) but not the MAX (Figure 3.8).
One-way ANOVA showed a significant drug effect on day 7 for the AUC
between the 0.07mg/kg dose and the following; 0.03mg/kg (p<0.001),
0.12mg/kg (p<0.001), WGA-HRP-AuNP (p<0.001), 0.07mg/kg AuNP-ProTHP
(p<0.001). There was significant drug effect for the MAX between the
0.07mg/kg dose and the following; 0.03mg/kg (p=0.013), WGA-HRP-AuNP
(p=0.027), 0.07mg/kg AuNP-ProTHP (p=0.013) (Figure 3.9). Interestingly all
control solutions at day 7 resulted in detectable recovery of the phrenic
nerve, however the level of recovery of the LPN in several groups was
negligible.
One-way ANOVA showed a significant drug effect on day 14 for the AUC
between the 0.03mg/kg dose and the 0.12mg/kg dose (p=0.030). There was
also a significant drug effect for the MAX between the 0.03mg/kg dose and
the remaining two doses 0.12mg/kg (p=0.001) and 0.07mg/kg (p=0.049)
(Figure 3.10).
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Figure 3-8 Day 3 Phrenic Nerve Recordings Analysis. The average percent
integrated (AUC) and average percent maximum amplitude (MAX) of the LPN
compared to the RPN. Statistical data consisted of neurograms from 18 rats.
One way ANOVA showed significant drug effect (#) on day 3 between the
0.12mg/kg dose group and the remaining two groups, 0.03mg/kg dose and
0.07mg/kg dose for the AUC (p<0.001). No significance was detected from
the MAX.
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Figure 3-9 Day 7 Phrenic Nerve Recordings Analysis. The average percent
integrated (AUC) and average percent maximum amplitude (MAX) of the LPN
compared to the RPN. Statistical data consisted of neurograms from 18 rats.
One way ANOVA showed significant drug effect on day 7 for the AUC
between the 0.07mg/kg dose and the following; 0.03mg/kg (p<0.001),
0.12mg/kg (p<0.001), WGA-HRP-AuNP (p<0.001), 0.07mg/kg AuNP-ProTHP
(p<0.001). There was significant drug effect for the MAX between the
0.07mg/kg dose and the following; 0.03mg/kg (p=0.013, *), WGA-HRP-AuNP
(p=0.027, **), 0.07mg/kg AuNP-ProTHP (p=0.013, ***).
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Figure 3- 10 Day 14 Phrenic Nerve Recordings Analysis. The average percent
integrated (AUC) and average percent maximum amplitude (MAX) of the LPN
compared to the RPN. Statistical data consisted of neurograms from 18 rats.
One way ANOVA showed significant drug effect (#) on day 14 for the AUC
between the 0.03mg/kg dose and the 0.12mg/kg dose (p=0.030). There was
also significant drug effect (†) for the MAX between the 0.03mg/kg dose and
the remaining two doses 0.12mg/kg (p=0.001) and 0.07mg/kg (p=0.049).

Based on statistical analysis of the neurograms, each dose had a
significant drug effect for the three different time points; 0.12mg/kg on day
3, 0.07 mg/kg on day 7, and 0.03 mg/kg on day 14. There was no single dose
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tested that produced consistently significant recovery for all time points
compared to the remaining doses. These data may reflect the inconsistent
synthesis of the theophylline nanoconjugate.

3.4 Discussions
The WGA component of the nanoconjugate was identified by
immunostaining in all three rats in the ipsilateral PN in the cervical spinal
cord and bilaterally in the rVRGs in the medulla. This shows that the WGAHRP component of the nanoconjugate was transported to the phrenic
nucleus and transsynaptically to the rVRG. However, this technique does not
confirm if theophylline is also located in the PN and rVRGs, which must occur
for the theophylline to stimulate the CPP. This is due to the hydrolysable
ester bond that enables the detachment of theophylline from the
nanoparticle carrier. The primary drug release from ester-based drug linkers
on nanomaterials is due to intracellular action of acid hydrolases in the acid
compartments such as endosomes (pH 5.0-6.0) and lysosomes (pH 4.8). (120)
Drug release from ester linkage to nanomaterials tends to be rather slow. For
example, only 5% methotrexate was released over a period of 72 hours from
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a dendrimer carrier in a serum medium at 37ºC. (121) In another study, less
than 5% of an antitumor drug SN38, a metabolite of irinotecan, released
from its nanocarrier after 24 h in PBS buffer. (122) In a third study, the ester
link of an immunosuppressive agent FK506 conjugated to dextran has a halflife of ~150 hours in a phosphate buffer (pH = 7.4). (123) We are currently
conducting in vivo experiments to determine the biodistribution of the
nanoconjugate as well as in vitro experiments simulating the in vivo
environments to quantify the theophylline release profile from the
nanocarrier.
The results from EMG analysis demonstrate that the nanoconjugate
doses 0.0005, 0.0008, 0.0025, 0.03, 0.07, and 0.12mg/kg stimulate recovery
of LHD activity detected as early as day 2 post injection and persisting up to
14 days. Again, based on literature it is likely significant amount of
theophylline is still attached to the nanocarrier at the time of detection of
LHD activity. Although current techniques are unable to confirm the
presence of theophylline in the PN and rVRGs in this study, we confirmed the
presence of WGA by immunostaining techniques. Recovery of the LHD
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appearing by day 2 post injection corresponds with the time required for the
uptake of WGA to the PN and rVRGs (94).
The control solutions, WGA-HRP-AuNP and 0.07mg/kg AuNP-proTHP
did not produce LHD recovery in any of the rats tested. It is interesting to
note that AuNP-proTHP was unable to produce LHD recovery even though
proTHP was present. The explanation behind this remains unclear; however,
without the WGA-HRP there is no transporter to initiate absorptive
endocytosis at the phrenic nerve terminals following injection, therefore the
drug should not have been delivered to the phrenic nuclei and rVRGs. It is
possible for the theophylline to be released in the muscle and have a
systemic effect but the dose administered via the nanoconjugate is a fraction
of that needed to stimulate CPP recovery following systemic administration
(97).
To better characterize the effect of the nanoconjugate, quantification
of bilateral nerve recordings under standard conditions were compared
between groups. The use of ketamine during a procedure to test for
respiratory activity may appear problematic. However, in this study all
recordings were sampled under the same protocol and there were no issues
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detecting activity of the phrenic nerve on the non-injured side. Future, in the
study by Giroux et al. (124), the effect of ketamine-xylazine anesthesia on
respiration in SD rats was described. Rats used in the current study were 1014 weeks of age (approximately 3 months) selected based on their weight.
The study by Giroux et al. (124), demonstrates that the concern of
respiratory depression following ketamine-xylazine use in younger adult rats
(3 months) is only of valid within the first 15-30 minutes after intraperitoneal
administration. At the 45-minute time point Giroux et al. (124), found that
respiratory frequency had returned to pre-dosing levels in rats 3 months of
age.
The variation of the AUC percent recovery observed for the 3
nanoconjugate doses over the course of the study might demonstrate the
drug dose effect on respiration as the drug is metabolized and lasting effects
over time. For all timepoints tested the 0.03mg/kg dose produced the
highest percent of LPN activity with an AUC of 2.2%, however this is modest
LPN recovery at best. Fortunately, in addition to theophylline there are
multiple drugs known to enhance respiration following high SCI including
DPCPX, a specific A1 adenosine receptor antagonist (109, 125). Simultaneous
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to this study AuNPs conjugated to WGA-HRP and DPCPX were being
investigated (108). Injection of the DPCPX coupled nanoconjugate
(0.15µg/kg DPCPX) produces an average percent recovery of 56.8% on day 7
and 72.4% on day 14 for the AUC of the LPN compared to the right phrenic
nerve (108). Further investigation into the use of the DPCPX nanoconjugate
is underway.
Throughout this work the chemical stability of the theophylline
nanoconjugate for in vivo application became apparent. To chemically link
theophylline to the AuNPs, a hydroxymethyl group was added to the
theophylline creating proTHP, which then forms an ester bond with the
capping agent, MSA, on the AuNPs following the Steglich reaction. The
synthesized ProTHP was originally stored in vials in ambient air. We
discovered that proTHP is reactive to moisture and hydrolyzes back to THP.
When comparing 2 nanoconjugate batches (not used in the study),
thermogravimetric analysis (TGA) detected a 5.7% weight variance, which is
the difference of 105 molecules of proTHP attached to each AuNP. The
hydrolysis tendency of proTHP poses significant challenges for the long-term
storage of the product for in vivo applications. Following the discovery of the
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apparent instability of proTHP we developed an experimental protocol to
characterize the drug concentration for every batch with TGA to verify
uniformity before in vivo use. The integrity of bond stability has been
emphasized by others (126). It was decided to limit the use of the
nanoconjugate for no longer than 30 days post synthesis. To further protect
proTHP from hydrolysis we stored the newly synthesized proTHP in argon
gas. We suggest that further investigation into the effects of the proTHPbound nanoconjugate should take proTHP hydrolysis into consideration and
carefully quantify the nanoconjugate chemical composition. Interestingly
WGA-HRP-AuNP-DPCPX nanoconjugate used in the Minic et al. (108) study
did not encounter the same issues stated above. In comparison to
theophylline, DPCPX is more hydrophobic with an additional 5-carbon ring, a
characteristic that may contribute to the chemical stability of pro-DPCPX
against hydrolysis.
To increase the stability of the AuNP-proTHP bond, an alternative chemical
bond was investigated. The nanoconjugate used in the work described
herein used a methyl-binding site; we later identified a version of the proTHP
compound that was coupled to the AuNPs using an ethyl-binding site. The
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change in the binding site resulted in less proTHP molecules bound per AuNP
requiring a higher AuNP concentration to maintain the same drug dosage.
The effectiveness of the proTHP-coupled nanoconjugate via an ethyl bond
was less than the methyl bond. Therefore, efforts to further investigate the
ethyl version were abandoned due to low effectiveness.
There were notable differences in the AuNP concentration between
solutions. To deliver an effective dose of proTHP, the AuNPs in solution were
at a concentration of 0.8 mg Au/ml, but at this concentration, we noticed
some degree of aggregation of the AuNPs. Nanoparticle aggregation in
biological milieu occurs frequently and this limits nanoconjugate uptake by
cells (e.g., via endocytosis). The concern of aggregation became evident
during an ongoing biodistribution study, while euthanizing rats that received
injections 8 weeks prior, the black appearance of the AuNPs, indicative of
AuNPs aggregation, was still visible in the diaphragm. If the AuNPs are still
visible in the muscle 8 weeks’ post injection one must consider the likelihood
of proTHP being delivered to the appropriate nuclei versus the proTHP bond
degrading in the muscle. To explore this concern, the concentration of the
AuNPs, along with the proTHP, was reduced in a stepwise manner to
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determine if by lowering the AuNP concentration the probability of AuNP
aggregation would be reduced and the probability of nanoconjugate uptake
and proTHP delivery would increase. Reduction of the AuNP concentration
in solution did result in a reduction of aggregation, as expected, which was
confirmed visually by a color change from pinkish red to dark blue, however
the effectiveness of proTHP failed to reach the level of recovery produced by
the DPCPX-coupled nanoconjugate. Interestingly the therapeutic dose of
DPCPX required only 0.1 mg Au/ml and therefore aggregation complications
never arose during the DPCPX study.
3.5 Conclusions
WGA-HRP-AuNP-proTHP nanoconjugates are capable of significantly
increasing the amount of LPN recovery when injected intradiaphragmatically
immediately after C2Hx compared to the control treatments. Targeting
delivery of theophylline reduces the therapeutic dose from 15mg/kg IV(97)
to less than 0.2mg/kg. In doing so the restored left hemidiaphragm and left
phrenic nerve function can be detected as early as 2 days and persists up to
day 14 post injection. However, the WGA-HRP-AuNP-proTHP nanoconjugate
used in this study fails to induce an equal amount of recovery following the
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administration of the WGA-HRP-AuNP-DPCPX nanoconjugate (108). The
clinical use of theophylline in humans led us to expend maximum effort to
find a combination of the proTHP coupled nanoconjugate to reach the
effectiveness of the DPCPX coupled nanoconjugate. However, the proTHP
nanoconjugate continued to present stability concerns both in terms of its
chemical stability in storage and colloidal stability post injection. The amount
of proTHP per AuNP for effective recovery requires an AuNP concentration
that is prone to aggregation, which limits the transport and cellular uptake
of the nanoconjugate. While it is possible to overcome these stability issues
by investigating alternative chemical conjugate chemistry, our lab has
already yielded a more promising nanoconjugate, DPCPX-containing
nanoconjugate

(108).

The

effectiveness

of

the

DPCPX

coupled

nanoconjugate well-surpassed those of proTHP, therefore all our future
efforts will be directed towards the DPCPX-coupled nanoconjugate.
Lastly, the application of the WGA-HRP-AuNP nanoconjugate is not
limited to the phrenic motor system. WGA-HRP has been applied over the
decades to identify many neuromuscular pathways. In theory, injection of
the WGA-HRP-AuNP nanoconjugate bound to a variety of substances could
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hold promise for investigation and treatment of multiple disease and injury
models.

CHAPTER 4 ANTI-CANCER DRUG CONJUGATED NANOPARTICLES INDUCED
CELL DEATH IN TRIPLE NEGATIVE BREAST CANCER CELLS
This chapter is reproduced with permission from the Molecular
cancer therapeutics 17, no. 12 (2018): 2586-2597. Saadat, Nadia, Fangchao
Liu, Brittany Haynes, Pratima Nangia-Makker, Xun Bao, Jing Li, Lisa A. Polin,
Smiti Gupta, Guangzhao Mao, and Malathy P. Shekhar. "Nano-delivery of
RAD6/Translesion Synthesis Inhibitor SMI# 9 for Triple-negative Breast
Cancer Therapy." And the Nanomedicine: Nanotechnology, Biology and
Medicine 12, no. 3 (2016): 745-757. Haynes, Brittany, Yanhua Zhang,
Fangchao Liu, Jing Li, Sarah Petit, Hend Kothayer, Xun Bao, Andrew D.
Westwell, Guangzhao Mao, and Malathy PV Shekhar. "Gold nanoparticle
conjugated Rad6 inhibitor induces cell death in triple negative breast
cancer cells by inducing mitochondrial dysfunction and PARP-1
hyperactivation: Synthesis and characterization."
4.1 Introduction
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The human homologues of yeast Rad6, HHR6A and HHR6B (referred
as Rad6A and Rad6B) play a fundamental role in DNA damage tolerance
pathway (127-130), and the ubiquitin conjugating activity of Rad6 is essential
for this function (131). The Rad6B homologue is overexpressed in metastatic
and

chemo-resistant

breast

carcinomas

(132-134).

Constitutive

overexpression of Rad6B in nontransformed human breast epithelial cells
induces tumorigenesis and resistance to cisplatin and doxorubicin (132, 135,
136). Conversely, Rad6B silencing renders cells chemo-sensitive (136),
implicating the relevance of Rad6 in transformation and drug resistance, and
the potential therapeutic benefit of inhibiting Rad6. We have recently
reported the development of a novel Rad6-selective small molecule inhibitor
SMI#9 that inhibits Rad6 ubiquitin conjugating activity (137). SMI#9
treatment suppresses proliferation and migration and induces apoptosis in
breast cancer cells but spares normal breast cells (137). However, SMI#9 has
poor aqueous solubility that limits its therapeutic efficacy. Here we
developed a drug delivery system that would improve its solubility and
uptake.
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Gold nanoparticles (AuNPs) are ideal drug delivery scaffolds because
they are nontoxic and nonimmunogenic (138, 139), and have good
biocompatibility and stability (140). Surface modification allows AuNPs to be
readily functionalized with multiple agents including chemotherapy,
oligonucleotides and proteins making them good delivery vehicles (141).
Several AuNP-based drugs have been developed by CytImmune with their
lead drug Aurimune (TNF bearing PEGylated gold nanoparticles) in clinical
trials.
This chapter will describe the synthesis of SMI#9-tethered AuNPs
using a chemistry that allows intracellular release of SMI#9. SMI#9-AuNPs
were characterized for size and ligand conjugation, and intracellular release
of conjugated SMI#9 by Fourier transform infrared spectroscopy (FTIR) and
liquid chromatography coupled tandem mass spectrometry (LC-MS/MS).
Intracellular uptake, localization, cytotoxicity and molecular responses to
AuNP-conjugated SMI#9 were evaluated in triple negative breast cancer
(TNBC) cells as TNBC represents a heterogeneous disease with poor clinical
outcomes and few targeted therapy options as they lack estrogen receptor,
progesterone receptor and Her2/neu amplification. We analyzed the
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responses to conjugated and free SMI#9 in two major subtypes of TNBC,
mesenchymal and basal types (142) to authenticate the functionality of
AuNP-tethered SMI#9. We show that the mesenchymal subtype is sensitive
to SMI#9-AuNP and that modified SMI#9 released from AuNP acts similarly
to unconjugated parent SMI#9.
4.2 Experimental methods
4.2.1 Materials
Sodium bicarbonate (NaHCO3), di-tert-butyl dicarbonate ((Boc)2O), 37%
formaldehyde (HCHO) solution, triethylamine (Et 3N), tetrahydrofuran (THF),
gold(III) chloride trihydrate (HAuCl4∙3H2O), sodium citrate tribasic dihydrate,
mercaptosuccinic acid (MSA), sodium borohydride (NaBH 4), dimethyl
sulfoxide (DMSO), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC), Nhydroxysuccinimide (NHS), and 4-dimethylaminopyridine (DMAP) were
purchased from Sigma-Aldrich.
4.2.2 Synthesis of gold nanoparticle (AuNP) and conjugation of Rad6
inhibitor SMI#9 to AuNP
Mercaptosuccinic acid (MSA)-capped AuNP (MSA-AuNP) was
synthesized as described as followed. Briefly, ice-cold 0.1 M NaBH4 solution
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was added with vigorous stirring to a solution of 0.25 mM HAuCl 4∙3H2O and
0.25 mM trisodium citrate. The pH was adjusted to 11, and 50 mg MSA was
added. The final solution was concentrated to 2.5 g (gold)/L by centrifugation
using 10,000 MW Amicon filters. SMI#9 was modified to enable AuNP
conjugation via an ester bond. To modify SMI#9, 1.5 mg SMI#9 was dissolved
in 0.5 ml tetrahydrofuran (THF; 50%, v/v) followed by addition of 10 mg of
NaHCO3 and 2.6 mg di-tert-butyl dicarbonate (Boc)2O. After 30 min reaction,
5 µl of HCHO and 5 µl of triethylamine (Et 3N) were added and the
hydroxymethylation reaction was allowed to proceed for 48 h. The solution
was then added to AuNP (2.5 g/L gold concentration) solution. The pH of the
solution was adjusted to 4.7 with MSA, and 2 mg 1-ethyl-3-(3dimethylaminopropyl) carbodiimide (EDC), 0.2 mg 4-dimethylaminopyridine
(DMAP), and 2 ml dimethyl sulfoxide (DMSO) were added to catalyze the
esterification reaction. After 40 h, the final solution was concentrated to 0.2
g mL-1 by centrifugation using 10,000 MW Amicon filters and desalted by
exchanges with deionized water.
4.2.3 Characterization of AuNP–drug conjugates
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SMI#9 conjugated to AuNP was characterized by thermogravimetric
analysis (TGA) on an SDT-Q600 Thermo-Gravity Analyser using air as the
supporting gas. The air flow rate was maintained at 100 ml/min, and sample
heated from 25 to 800 °C at a rate of 10 °C/min. AuNP “solutions” were also
characterized by UV–vis spectroscopy with a Varian Cary® 50 spectrometer
in 2 mm optical path cells, and by transmission electron microscopy (TEM) at
200 kV with a JEOL JEM-2010 microscope equipped with a Gatan multiscan
CCD camera.
Dynamic light scattering (DLS) and zeta potential were measured using
a Malvern Nano-ZS. The Z-average hydrodynamic diameter (HD),
polydispersity index (PDI), and zeta potential were measured at 25 °C. 15
scans were performed in each measurement.
4.2.4 Cell lines and culture
MDA-MB-231 (BRCA1 wild-type) and MDA-MB-468 (BRCA1 wild-type)
human TNBC cells were purchased from ATCC, and SUM1315 (BRCA1 mutant)
TNBC cells were purchased from Asterand. All lines were maintained in
DMEM/F12 (Invitrogen) containing 5% FBS. Following authentication by cell
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bank (short tandem repeat PCR) and Mycoplasma screening (MycoAlert,
Lonza), several aliquots of cells were frozen and used within 10 passages.
4.2.5 SMI#9 and SMI#9-AuNP uptake and intracellular release of the
free drug from AuNP conjugate
MDA-MB-231 (3 × 105) cells were plated in 35 mm dishes and exposed
to various doses of SMI#9-AuNP or untreated for 24-48 h. Cultures were
rinsed, lysed by freeze–thaw cycles in cold hypotonic buffer, and clarified by
centrifugation at 10,000g. Aliquots of clarified lysates were analyzed by FTIR
spectroscopy using control lysates spiked with free SMI#9 as reference. To
determine intracellular release of modified SMI#9 from nanoparticles,
SUM1315 (2 × 106 cells/100 mm dish) cells were exposed for 8 or 24 h to 5
μM free SMI#9, 5 μM SMI#9-AuNP or the corresponding amount of blankAuNP, or untreated. Cultures were rinsed in ice-cold phosphate buffered
saline (PBS), lysed with cold 80% methanol and clarified by centrifugation at
10,000g for 10 min at 4 °C. Aliquots of supernatants were subjected to high
performance liquid chromatography (HPLC) coupled with tandem mass
spectrometry (LC-MS/MS) analysis.
4.2.6 Mitochondrial assay
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The impact of free SMI#9 or SMI#9-AuNP on mitochondrial membrane
potential (Δψm) on SUM1315 and HCC1937 TNBC cells was assessed using
JC-1 (Mitocapture, Biovision, Mountainview, CA), a potentiometric green
fluorescent dye that shifts to red fluorescence within mitochondria with a
normal negative Δψm. Briefly, cells were incubated with the MitoCapture
reagent for 15 min at 37 °C and imaged by fluorescence microscopy. The
percent of cells showing > 5 punctate J-aggregates was scored by counting
three-five fields of 50-100 cells in each field. To quantitate mitochondrial
membrane potential changes, 20 × 103 SUM1315 or HCC1937 cells were
seeded in 96-well plate and treated for 48 h with 5 μM SMI#9-AuNP or blankAuNP. Cells were then incubated with 10 μM JC-1 for 30-60 min, and the red
and

green

fluorescence

intensities

of

JC-1

were

measured

at

excitation/emission = 490/525 nm and 490/590 nm with a Synergy 2
fluorescence reader. Results were expressed as the ratio of red to green
fluorescence.
4.2.7 LC/MS-MS analysis of SMI#9
SMI#9 concentrations in the plasma and tumors were determined by
LC/MS-MS. Briefly, tumors (50–100 mg) were homogenized, and plasma or
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tissue homogenates were extracted with ethyl acetate. The organic phase
was dried down and reconstituted in the mobile phase [methanol/0.45%
formic acid in water (60:30, v/v)]. LC/MS-MS was performed on a Waters
Xevo TQ-XS LC/MS-MS system with a Waters Xterra MS C18 column and
isocratic elution with the mobile phase. SMI#9 was monitored at the positive
electrospray ionization mode at m/z 366.69 > 150.1 mass transitions.
4.2.8 Inductively coupled plasma mass spectrometry analysis of gold
Organs and tumors were digested with aqua regia (hydrochloric acid:
nitric acid, 3:1 v/v) and analyzed using an Agilent 7700× inductively coupled
plasma mass spectrometry (ICP-MS) equipped with an Agilent ASX-500 series
autosampler. External calibration using standards with internal standard
correction of bismuth (Bi) was performed prior to the measurements. AuNP
biodistribution data were expressed as a percentage of injected dose of
gold/gram dry tissue.
4.2.9 Statistical analysis
Each experiment was performed in triplicate and reproduced at least
three times. Data are expressed as mean ± S.D, and P < 0.05 determined by
Student’s t-test was considered to be statistically significant.
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4.3 Results
4.3.1 AuNP conjugates characterization
The chemical compositions of AuNP and SMI#9-AuNP were
determined by TGA. Figure 4.1A shows the TGA curves of MSA-AuNP (blankAuNP) and MSA-AuNP conjugated SMI#9 (SMI#9-AuNP) with weight loss of
6.15% and 13%, respectively, at 800 °C. The number of gold atoms was based
on size determined by transmission electron microscopy (TEM) and gold
density. The weight of 1 molar AuNP (W) with a diameter (D) of 4 nm can be
estimated using the following formula based on the bulk density of gold ():

(

)

3
1
g
1
W =   D3  6.022 10 23 = 19.3 3   4 10 −7 cm  6.022 10 23 = 3.89 105 g / mol
6
cm 6

The molecular weight of MSA (C4H6O4S) and SMI#9 (C17N6H14O4) are
150 g/mol and 366 g/mol, respectively. The weight loss, 93.85%:6.15% =
AuNP:MSA, corresponds to 170 MSA molecules per AuNP as calculated
below:
No. of MSA molecules =

6.15 3.89 105

= 170
150
93.85
.

The area of MSA coverage on AuNP (A) is calculated below:
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A=

D 2
No. of MSA molecules

=

 (4nm )2
170

2
= 0.296 nm 2 = 29.6

.

The weight loss, 100%:6.6%:8.3% = AuNP: MSA:SMI#9, corresponds to
88.2 SMI#9 as calculated below:
No. of SMI#9 molecules =

8.3 3.89 105

= 88.2
366
100
.

This means that 26% of all possible reactive sites (170 MSA molecules
carrying 340 –COOH groups) are conjugated with SMI#9.
Figure 4.1B shows the UV-vis spectra of AuNPs before and after
conjugation with modified SMI#9. The surface plasmon resonance (SPR)
absorption peak of freshly prepared AuNPs is 508 nm, which corresponds to
AuNP diameter range of 3-5 nm. However, upon conjugation with modified
SMI#9, the SPR absorption peak broadened and shifted to 524 nm, which is
indicative of particle aggregation. The size of SMI#9-AuNPs was also
determined by TEM (Figure 4.1C) and AFM (Figure 4.1D) which showed a size
of 32 nm and 40.2 ± 1.4 nm, respectively, that is consistent with aggregation.
DLS further verified the average size of SMI#9-AuNP nanoconjugate at 41 nm
as compared to 4.8 nm for AuNP. The zeta potential of MSA-capped AuNP
changed from -41 mV to -16.2 mV after conjugation with SMI#9. The
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decrease in surface charge is the result of SMI#9 conjugation to highly
charged MSA.
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Figure 4-1 SMI#9-AuNP characterization. A) thermogravimetric analysis. B)
UV–vis spectroscopy. C) Transmission electron microscopy. D) Atomic force
microscopy (AFM). (a) AFM height of SMI#9-AuNP, Z-range = 5 nm. Inset in
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panel D(a) shows a white line from where the AFM sectional height profile in
panel D(b) was taken and shows 39 nm particle width (two arrows).
4.3.2 Intracellular SMI#9-AuNP uptake and releases
To determine SMI#9-AuNP uptake and intracellular release of the
conjugated SMI#9, MDA-MB-231 or SUM1315 cells were exposed to SMI#9AuNP, blank-AuNP, SMI#9 or untreated, and cell lysates analyzed by FTIR or
LC-MS/MS. Control cell lysates spiked with (parent) SMI#9 were included as
reference controls. FTIR analysis of SMI#9 (Figure 4.2A), and lysates
prepared from SMI#9-AuNP treated MDA-MB-231 cells or MDA-MB-231
control lysates spiked with SMI#9 showed characteristic nitro group banding
at ~ 1550 cm-1 , indicative of SMI#9 presence (Figure 4.2B).

Figure 4-2 FTIR spectra of A) chloroform/methanol (11:1, v/v) without (green)
and with SMI#9 (red). And of B) SMI#9-AuNP treated and control MDA-MB231 lysates spiked with parent SMI#9. Arrow indicates nitro banding.
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SMI#9 was modified to enable conjugation to AuNP via an ester bond
(Figure 4.3 A, a). Intracellular hydrolysis would result in release of modified
SMI#9 with the molecular weight of 396.3, which would theoretically
produce parent ions at 397.3 ([M+H]+) and product ions at 150.1 (Figure 4.3
A, b and c). Although no peak was detected under the transition of 397.3 >
150.1 in SMI#9-AuNP treated cells, a strong peak was detected under
m/z 381.3 > 150.1 transition in SMI#9-AuNP treated cells (at both 8 and 24
h) but not in blank-AuNP or untreated control cultures (Figure 4.? C). Release
of drug with 381.3 molecular mass could theoretically arise by
dehydroxylation of hydroxymethylated SMI#9; however, the precise
structure of intracellularly released drug and its metabolic processing is
under investigation. The peak signals were stronger at 8 h as compared to 24
h, suggesting rapid intracellular processing. The positive control cells treated
with free (parent) SMI#9 showed the expected peak under m/z 366.69 >
150.1 transition.

These results suggest efficient uptake and rapid

intracellular processing of the chemically modified SMI#9-AuNP conjugates.
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Figure 4-3 LC-MS/MS analysis of SMI#9 release. A) (a) Chemical structures of
parent SMI#9 (MW = 366.1), and AuNP-conjugated hydroxymethylated
SMI#9 (MW = 396.3). (b) Predicted fragmentation pathway of SMI#9 under
the MS condition. (c) Proposed mechanism of SMI#9 release from AuNP
conjugate. B) and C) Chromatograms of SUM1315 extracts prepared at 8 or
24 h from untreated (control), or cells treated with blank-AuNP (blank NP), 5
μM SMI#9 (B), or 5 μM SMI#9-AuNP (C, 9-NP). Samples were monitored at
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m/z 366.69 → 150.1 for SMI#9 (B) or m/z 381.3 → 150.1 for SMI#9 released
from AuNP (C).
4.3.3 In vivo evaluation of SMI#9 and SMI#9-AuNP
SMI#9 concentrations in plasma were measured by LC-MS/MS at 5 min
to 24 h after a single intravenous injection of SMI#9 or PEGylated SMI#9AuNP. Following injection of the unconjugated drug, SMI#9 achieved
maximum plasma concentration (Cmax) of ~74 nM at 5 min, and was rapidly
cleared by 30 min (Figure 4.4A). In contrast, following injection of SMI#9AuNP, SMI#9 was slowly released and achieved Cmax of ~1200 nM at 8 h
(Figure 4.4B). These data suggest that SMI#9 is not only released from the
PEGylated SMI#9-AuNP conjugates but can also achieve higher systemic
exposure as compared to the unconjugated SMI#9.
Post-synthesis surface modification of SMI#9-AuNP with PEG was
performed as PEG improves colloidal stability and prevents aggregation (143,
144). Furthermore, PEG reduces adsorption of cellular proteins and increases
the circulation time of nanoparticles. We first determined whether
PEGylated SMI#9-AuNP similarly sensitizes TNBC cells as non-PEGylated
SMI#9-AuNP. SUM1315 cells were treated with various concentrations of
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SMI#9-AuNP or PEGylated SMI#9-AuNP (or blank-AuNP) and the responses
measured by MTT assays. SUM1315 cells responded similarly to both
formulations with GI50 values (based upon SMI#9 concentration) of ~0.75-1
M, verifying that tethering of PEG did not significantly affect the activity of
SMI#9 payload (Figure 4.4C). To compare the in vivo effects of SMI#9 and
PEGylated SMI#9-AuNP or blank-AuNP on TNBC xenografts, MDA-MB-468 or
SUM1315 TNBC cells were orthotopically implanted in female nude mice.
When the tumors reached ~150 mm3, mice were randomized and treated
twice weekly with vehicle, SMI#9, PEGylated SMI#9-AuNP or blank-AuNP. To
overcome SMI#9 solubility limitations and to facilitate easy tumor access,
unconjugated SMI#9 (or vehicle) was administered intratumorally whereas
blank-AuNP and SMI#9-AuNP were injected intraperitoneally to assess
tumor accessibility and bioavailability. Animal body weights were measured
twice weekly to monitor animal health. SMI#9 or SMI#9-AuNP treatments
significantly inhibited growth of MDA-MB-468 and SUM1315 xenografts as
compared to the corresponding vehicle or blank-AuNP control groups (P ≤
0.05; Figure 4.4D and E). Compared to the control tumors that contained
mitotic cells, H&E analysis of SMI#9 and SMI#9-AuNP treated MDA-MB-468
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(Figure 4.4F) and SUM1315 (Figure 4.4G) tumors showed sparsely populated
tumor tissues containing apoptotic cells (arrows in insets of Figure 4.4F and
G). H&E staining showed lung tissues with normal architecture in both
control and SMI#9 or SMI#9-AuNP treated groups (Figure 4.4H). The data in
Figure 4.4I show that SMI#9 and SMI#9-AuNP treated mice maintain body
weights comparable to vehicle or blank-AuNP controls suggesting drug
tolerance without overt signs of toxicity.
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Figure 4-4 SMI#9-AuNP inhibits TNBC growth. Pharmacokinetic analysis of
unconjugated SMI#9 (A) and PEGylated SMI#9-AuNP (B) administered
intravenously at 5 mg/kg body weight. C) In vitro activities of SMI#9-AuNP
and PEGylated SMI#9-AuNP on SUM1315 cell proliferation. Results are mean
± SD of triplicates from two independent experiments. Tumor volumes
(mean ± SEM; n = 6 mice/group) of MDA-MB-468 (D) or SUM1315 (F)
xenografts treated with unconjugated SMI#9 (1.5 mg/kg body weight),
PEGylated SMI#9-AuNP (0.85 mg/kg body weight), or controls. P < 0.0001 by
one-way ANOVA. Vertical scatter plots of excised tumor mass of MDA-MB468 (E) and SUM1315 (G) xenografts.
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4.3.4 Biodistribution of SMI#9-AuNP
To verify whether the tumor growth inhibition in SMI#9-AuNP–treated
mice resulted from SMI#9 release from the nanoconjugate, we quantitated
SMI#9 levels in tumor fragments collected at sacrifice by LC/MS-MS.
Compared with the control groups, measurable amounts of SMI#9 were
detected in SUM1315 and MDA-MB-468 tumors treated with SMI#9 or
SMI#9-AuNP (Figure 4.5 A and B). However, there was variability in the
detected levels, which could have potentially resulted from tumor tissue
samplings as tissue fragments rather than whole tumors were used for
analysis or from loss of SMI#9 resulting from therapy-induced tumor cell
death in the responsive tumors.
Next, we determined the biodistribution and retention of AuNPs in
tumor and organ tissues collected at sacrifice (Figure 4.5 C) by ICP-MS. The
injected dosage of gold was calculated on the basis of the TGA data: weight
ratio of gold to SMI#9 equivalent to 1:0.083 in the nanoconjugate (143). Thus,
a SMI#9 dosage of 0.85 mg/kg body weight corresponds to gold dosage of
10.24 mg. On the basis of 0.02 kg average weight of mouse, the gold dosage
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per injection is 0.2 mg and the total gold injected is 1.8 mg after nine
injections. Among the tissues analyzed, liver and tumors showed the highest
accumulation of gold ranging from 0.19% to 0.4%; however, there were no
significant differences in gold content between livers and tumors of blank
AuNP and SMI#9-AuNP groups (Figure 4.5 C). Despite multiple injections, this
accumulation was comparable with those reported for a single injection
(145). AuNP bioaccumulation in liver and spleen are regulated by the
reticuloendothelial system (RES; (146)). The low levels of AuNP accumulation
in the spleen potentially reflect the low AuNP doses administered in our
study and/or the time intervals between the injections. Furthermore,
because the tissue samples were collected 3 days after the last AuNP
injection, larger increases in gold depositions were perhaps not observed
because of active renal clearance. The AuNPs used here are 5-nm particles
with a hydrodynamic size of 41 nm following SMI#9 conjugation. Because the
kidney filtration threshold is 6–8 nm (147), AuNPs that were stripped off their
SMI#9 cargo would be small enough to be cleared by the kidneys leaving
behind the non-biodegraded SMI#9-AuNPs. Because tumors contained
higher levels of gold, it is likely that enhanced permeability and retention

87

(EPR) effects from leaky vasculature in the tumors contributed to
accumulation of gold in the tumors (Figure 4.5 C).

Figure 4-5 SMI#9 and gold biodistribution analysis. LC/MS-MS analysis of
SMI#9 tumor levels and corresponding vertical scatter plots of SUM1315 (A)
or MDA-MB-468 (B) excised tumor mass at sacrifice. C) ICP-MS analysis of
accumulated gold in the indicated tissue. Data were analyzed by one-way
ANOVA and two-tailed Student t test; NS, no significant difference.
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4.4 Discussions
Intratumoral injection of SMI#9, a clinically unsuitable mode of drug
administration, was necessary because of its poor solubility and poor
pharmacokinetic properties. Delivery of SMI#9 as a prodrug–AuNP conjugate
not only greatly improved its circulation stability and drug exposure, but also
allowed for a clinically acceptable mode, that is, systemic administration of
the drug because of improved solubility. In this work we evaluated the
toxicity,

biodistribution,

and

therapeutic

activity

of

systemically

administered PEGylated SMI#9-conjugated AuNPs to assess their utility as a
drug delivery platform for treatment of BRCA1 wild-type and BRCA1-mutant
TNBCs.
Perrault and colleagues (148) tested AuNPs with size range of 10–100
nm and found that although AuNPs with hydrodynamic diameter of 60–100
nm with PEGylation efficiently utilize EPR effect for enhanced tumor
accumulation, these larger AuNPs penetrated weakly into the tumors and
localized in the perivascular regions. AuNPs are generally considered
nontoxic when the size is larger than 2 nm, whereas ultrasmall nanoparticles
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are found to be toxic (149). AuNPs of larger size (35–50 nm) were found to
enter cells more efficiently without toxicity than small nanoparticles (1.4 nm;
(150)). Consistent with these data, our results show that 41-nm SMI#9AuNPs are taken up efficiently by tumor cells and display no apparent toxicity.
Quantitative analysis of AuNP biodistribution by ICP-MS analysis showed
higher accumulation of gold in tumors and liver as compared with other
organs of SMI#9-AuNP and blank AuNP–treated mice. These data are in
agreement with other studies that showed maximal accumulation of
nanoparticles in the liver regardless of their size, shape, dosage, or
composition (146, 151, 152). However, our data suggest that the AuNPs are
actively cleared because the amounts of gold deposited in the liver and other
tissues despite repeated injections resemble those in mice receiving a single
dose. Because the AuNPs used in our study have a 5-nm core diameter and
a hydrodynamic size of 41 nm for the SMI#9 nanoconjugate, our data suggest
that the majority of AuNPs are stripped off their SMI#9 payload rendering
them small enough for renal clearance (147). These data are consistent with
those reported by Perrault and colleagues who showed rapid clearance of
PEGylated 20-nm and 40-nm AuNPs from circulation without accumulation
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in the spleen and liver (148). Regardless of the coating layer, nanoparticles
always form a “protein corona” when encountering physiologic conditions
(153, 154). This corona phenomenon potentially balances out any
differences between blank AuNP and SMI#9-conjugated AuNP during
circulation and may explain the similar patterns of biodistribution data. It is
noteworthy that despite high accumulation of gold in the tumors of blank
AuNP–treated mice, tumor growth was unaffected in these mice providing
further support for SMI#9 therapeutic activity and the nontoxicity of AuNPs.
Although tumor growth was robustly inhibited by SMI#9-AuNP, the
treatment did not affect body weights or induce overt toxicity as determined
by necropsy and histopathologic analysis of the major vital organs.
4.5 Conclusions
In summary, the mechanistic data presented here show that AuNP is
a suitable vehicle for delivering SMI#9 and that the chemically modified
SMI#9 released from AuNP functions similarly as the free parent SMI#9. we
demonstrated the therapeutic utility of an AuNP-based platform for
delivering Rad6 inhibitor for treating BRCA1 wild-type and BRCA1-mutant
TNBCs, a breast cancer subtype with poor prognosis and no targeted
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therapies. SMI#9 delivery as a prodrug–AuNP conjugate not only improved
its pharmacokinetic properties but also allowed for a clinically acceptable
(systemic) mode of drug administration that inhibited TNBC growth. There
was no evidence of blank or SMI#9-AuNP–induced toxicity as measured by
their impact on animal body weight and organ histopathology.

CHAPTER 5 SIZE-DEPENDENT TOXICITY OF GOLD NANOPARTICLES
This chapter is reproduced with permission from the Small, 12, no. 5
(2016): 631-646. Marie‐Claude Senut, Yanhua Zhang, Fangchao Liu, Arko
Sen, Douglas M. Ruden, Guangzhao Mao, “Size-dependent toxicity of gold
nanoparticles on human embryonic stem cells and their neural derivatives”.
5.1 Introduction
Nanotoxicology is an emerging discipline studying the interference of
engineered nanomaterials with the functions of cellular and extracellular
nanomachineries.(155)

The

accelated pace

of clinical trials

and

commericalization of nanomaterials places increased demands on
toxicological evaluations of engineered nanomaterials.(156) There is an
urgent need to develop predictive and validated nanotoxicological
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assessment methods for nanomaterials due to their unique size range,
surface

chemistry, and interactions with biological

systems.(157)

Nanomaterials have the potential to cross the placental and the blood-brain
barriers(2, 158) or, in a few examples, be transported to the central nuervous
system

(CNS)

without

crossing

the

blood-brain

barrier.(159-162)

Neurotoxicity of engineering nanomaterials will become more relevant with
the development of CNS-targeting nanomedicine.
Because of the wide biomedical applications of AuNPs, human
exposure to AuNPs will be increasingly likely, which warrants careful
evaluation of their toxicological effects. AuNPs have been described by most
studies as nontoxic,(139, 163-165) but some studies have found them to be
toxic.(166-172) AuNPs with 1.4-1.5 nm in diameter have been found to be
highly toxic to cells.(168, 173) A few in vitro and in vivo studies have shown
that chronic exposure to AuNPs might interfere with brain function. For
example, a decrease in glutamate decarboxylase 1, an enzyme that is
involved in GABA synthesis and is associated with several neurological
disorders,(174) was observed in human HeLa cells exposed to gold
nanorods.(175) Exposure to high concentrations of 20 nm AuNPs was found
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to increase the proliferation in human neurosphere-derived neural
precursor/pregenitor cells (NPCs)(176) and induce oxidative stress in a
mouse immortalized NPC line.(177) In rodent models, intraperitoneal
injections of 17-20 nm AuNPs resulted in learning and memory deficits
associated with elevated dopamine levels and decreased serotonin
levels,(178) as well as increased brain expression levels of markers of
oxidative stress, apoptosis, and inflammation.(179) More recently, cultured
mouse hippocampal CA1 neurons were shown to be more excitable when
exposed to 5-40 nm AuNPs.(180) Taken together, these data demonstrate
that AuNPs as tools for neuromedicine should be carefully evaluated since
they may adversely alter neuronal differentiation, synapse formation, and
functional plasticity (which affect memory and learning) in a size-dependent
manner.
Currently, there are no systematic methods to predict toxicological
effects of AuNPs on human health. A majority of neurotoxicological
assessments are conducted in vitro using immortalized cell lines with
standard toxicological assays such as the MTT (measurement of
mitochondrial enzymatic activity) and LDH (measurement of cell membrane
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disruption) assays with short exposure time (usually limited to within 48
hours). One shortcoming of standard in vitro toxicity assays, however, is that
the potential interference of nanoparticles with embryonic development
cannot be clearly addressed. Furthermore, it is often difficult to correlate
outcomes from animals to humans. Human embryonic stem cells
(hESCs)(181) and their subsequent differentiation into NPCs and neurons
have enabled researchers to establish pluripotent cell-based models to study
developmental neurotoxicology. This process mimics aspects of the early
stages of human brain development, giving us a unique opportunity to
identify the effects of exposure to nanomaterials on neural specification.
Some significant advantages in using hESCs compared to other (e.g., animalderived) systems are that 1) they have unlimited self-renewal capabilities
and can be grown indefinitely in the laboratory; 2) they can differentiate into
a variety of specialized cell types, such as neurons; 3) they preclude speciesspecific differences, making them a better model to predict human response
to toxins; and 4) subtle changes in cell functionality rather than cell death
can be tested on nanomaterials of low toxicity such as AuNPs. Recently,
mouse ESCs were used to evaluate the neurotoxicity of AuNPs.(182, 183)
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This chapter describes the morphological and epigenetic effects of
AuNPs of three core sizes (1.5 nm, 4.0 nm, and 14 nm) on the neuronal
differentiation of hESCs. The 1.5 nm AuNP (AuNP1.5) was chosen because
AuNPs of this size have been found to be highly toxic to cells.(168, 173)
AuNP4 and AuNP14 are within the size range widely used for targeted drug
delivery applications including those targeting the brain.(2, 3) The
nanoparticle size and surface chemistry were characterized by UV-vis, AFM,
TEM, and zetasizer. We show that AuNPs have size-dependent differential
effects on the viability, pluripotency, and neuronal differentiation potentials
of hESCs.
5.2 Experimental methods
5.2.1 Materials
Gold(III) chloride trihydrate (HAuCl4·3H2O, 99% metal trace),
chloro(triphenylphosphine)gold(I) (AuCl(PPh 3), 97%), sodium citrate tribasic
dehydrate (≥99%), MSA (97%), borane tert‐butylamine complex (97%),
sodium

borohydride

(NaBH4)

(98%),

polyamidoamine

(PAMAM,

ethylenediamine core) dendrimer G0.5 (powder) and G1.5 (methanol
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solution), and bovine serum albumin (BSA, 98%) were all purchased from
Sigma‐Aldrich. Sodium hydroxide (98%) was purchased from Fisher Scientific.
5.2.2 AuNP Synthesis and Characterization
Thiolate‐capped 1.5 nm ultrasmall AuNP (AuNP1.5) were synthesized
by modifying a literature procedure.(184) The Au(I) precursor AuCl(PPh3)
(0.375 mmol) was partially dissolved in 21 mL ethanol at room temperature
under vigorous stirring (600–800 rpm). Tert‐butylamine‐borane (3.75 mmol)
was used as a mild reducing agent, and 2 h after its addition, MSA (0.15 mmol)
was added to control the particles size.(185) Mercapto‐alkyl acids have been
found to be effective in stabilizing ultrasmall AuNPs in aqueous solution. The
final AuNP ethanol solution was washed and purified by ultracentrifugation
using MW10000 Amicon centrifuge tubes in deionized water repeatedly.
MSA-capped 4 nm AuNP (AuNP4) were synthesized following a modified
literature procedure.(16) A 500 mL aqueous solution containing 0.25 × 10−3
M of HAuCl4·3H2O and 0.25 × 10−3 M of trisodium citrate was prepared in an
Erlenmeyer flask under vigorous stirring at room temperature. Then, 15 mL
of ice cold 0.1 M NaBH4 solution were added to the solution, resulting in a
change of the color solution to pink, indicative of the AuNP formation. After
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adjusting the pH of the solution to 11 with 0.1 M NaOH solution, 50 mg MSA
was added and the solution was stirred for 12 h. The final solution was
concentrated to 2.5 g (gold) L−1 by ultracentrifugation using MW10000
Millipore Amicon centrifuging units and washed by deionized water several
times.
Citrate-capped 14 nm AuNP (AuNP14) were synthesized using the
Turkevich method.(186, 187) In a typical synthesis, a 500 mL aqueous
solution containing 0.25 × 10−3 M HAuCl4·3H2O was heated to boil and then
175 mg of sodium citrate dissolved 30 mL water solution was directly poured
into the reaction mixture. The color of the reaction turned gray, pink, and
finally wine-red. The final solution was concentrated to 2.5 g (gold) L−1 by
ultracentrifugation using MW10000 Millipore Amicon centrifuging units and
washed by deionized water several times.
To apply the BSA coating, nanoparticle with concentration of 1 mg
(gold) ml-1 of deionized water was incubated overnight with 400 mg BSA.
Varian Cary 50 UV–vis absorption spectroscopy was used to determine
AuNP sizes, based on the Beer–Lambert law, with a scan range of 200–800
nm.
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TEM images of AuNPs were taken on JEOL JEM‐2010. The samples
were prepared by placing a droplet of the AuNP solution on a Formvar‐
coated copper TEM grid. Excess liquid was removed by a piece of filter paper
under the grid and dried in the air. The working voltage was 200 keV and the
current was 109 mA. At least 50 particles were measured on the same
sample to yield an average particle size.
DLS and zeta potential were measured using a Malvern Nano‐ZS. 1 mL
solution was transferred to a 2.0 mL polystyrene cuvette. The Z‐average
hydrodynamic diameter (HD), polydispersity index (PDI), and zeta potential
were measured at 25 °C. 15 scans were performed in each measurement.
5.2.3 Cell culturing and assay study
Human Embryonic Stem Cell Cultures: The NIH‐approved and
registered WA09 hESC line (passages 26–32; WiCell Research Institute,
Madison, WI, USA)(188) was maintained in a humidified incubator at 37 °C
with 5% CO2 as previously described.(189) Briefly, cells were grown on a
feeder layer of irradiated mouse embryonic fibroblasts (GlobalStem,
Rockville, MD, USA) in hESC culture medium made of 20% knockout serum
replacement, 2 × 10−3 M l‐glutamine, 1% nonessential amino acids, 1%
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penicillin/streptomycin (all products from Life Technologies Corporation,
Carlsbad, CA), 4 ng mL−1 human fibroblast growth factor basic (FGF2,
Peprotech, Rocky Hill, NJ), and 0.1 × 10−6 M 2‐mercaptoethanol (Sigma‐
Aldrich, St Louis, MO) in DMEM/F12 (Life Technologies Corporation, Carlsbad,
CA). The active ingredient within the serum replacement is lipid‐rich albumin.
hESCs were regularly passaged by mechanical dissection and their
pluripotent

state

assessed by immunofluorescence

detection for

pluripotency markers, such as Oct4, Nanog, and Lin28.
Trypan Blue Exclusion Assay: At the end of exposure, control and
AuNP‐treated hESCs were harvested and stained with 0.4% Trypan blue (Life
Technologies Corporation, Carlsbad, CA). Viable (unstained) and nonviable
(dark‐blue stained) cells were counted with a hemocytometer. The number
of viable cells was determined by subtracting the number of nonviable cells
from the total number of cells counted and expressed as a percentage
relative to the total number of cells. Data were collected from three
independent experiments.
MTT Assay: hESCs were cultured in phenol red‐free culture medium
and plated at a density of 100 000 cells per well of a 12‐well plate. At the end
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of AuNP exposure, the medium was supplemented with 0.5 mg mL −1 of MTT
(Sigma‐Aldrich, St Louis, MO) freshly prepared in PBS, and cells were
incubated in the dark at 37 °C for 3 h. MTT‐formazan crystals were then
solubilized for 15 min, at room temperature in dimethyl sulfoxide (DMSO).
Absorbance was measured at 590 nm using a spectrophotometer, and cell
survival was expressed as a percentage of absorbance relative to that of
control samples. Data were obtained from three separate experiments.
Uptakes Studies by TEM: The cellular uptake of AuNPs was assessed
on MEFs and undifferentiated WA09 cells (passage 32) exposed to vehicle or
10 μg mL−1 AuNP14 for 48 h. At the end of exposure, cells were washed and
fixed in 2.5% glutaraldehyde (Electron Microscopy Sciences, Hatfield, PA) in
PBS. Samples were processed at the MSU Center for Advanced microscopy
where they were postfixed in 1% osmium tetroxide, rinsed in distilled water,
dehydrated through a graded series of acetone, and embedded in epoxy
resin. Ultrathin 70 nm sections were obtained and then analyzed and
photographed using a JEOL 100CXII electron microscope.
Pluripotency In Vitro Studies: The effects of exposure to AuNPs on the
in vitro pluripotency capabilities of hESCs were determined using
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spontaneous differentiation of EBs.(190) Briefly, EBs were generated by
mechanical dissociation of hESC colonies and cultured for two weeks in FGF2‐
free hESC medium in presence of vehicle, 0.6 μg mL −1 AuNP1.5, or 10 μg mL−1
of AuNP4 and AuNP14. At the end of exposure, total RNA was extracted from
EBs using Qiazol (Qiagen, Valencia, CA) according to the manufacturer's
protocol, quantified by optical density, and subjected to reverse
transcription using Superscript II Reverse Transcriptase and random primers
(Life Technologies Corporation, Carlsbad, CA) for 50 min at 40 °C followed by
15 min at 75 °C. Quantitative PCR analyses of the well‐established lineage
marker genes—endodermal (AFP and NODAL), ectodermal (NCAM and
NESTIN), and mesodermal (BRACHYURY, PITX2, and LEFTY)—were
performed using an ABI PRISM 7000 Sequence Detection System and its
software (Applied Biosystems) with 10 ng cDNA, 400 × 10−9 M of each primers,
and SYBR Green PCR Master Mix (Life Technologies Corporation, Carlsbad,
CA). Resulting data were normalized against the expression of the internal
control GAPDH gene. Data analysis was performed using the 2 − ΔΔCt
method (Livak and Schmittgen 2001) and standardized by log transformation,
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mean centering, and autoscaling as previously described.(191) Data were
collected from three separate experiments.
Differentiation of hESCs into NPCs: Generation of NPCs from hESCs
was performed as previously described.(189, 192) Following mechanical
dissociation of hESC colonies, EBs were cultured in suspension for 4 d in 1:1
hESC/N2 medium (Life Technologies Corporation, Carlsbad, CA), followed by
4 d in N2 medium supplemented with 3 × 10−6 M retinoic acid (RA; Sigma‐
Aldrich, St Louis, MO), and 3 d in N2 medium added with 20 ng mL−1 FGF2
(Peprotech, Rocky Hill, NJ). At this time, EBs were transferred to fibronectin‐
coated plates (20 μg mL−1 fibronectin; Life Technologies Corporation,
Carlsbad, CA) and cultured in N2/FGF2 medium for an additional 8 d to obtain
neural rosettes. The latter were subsequently dissociated and plated in
N2/FGF2 medium on 10 μg mL−1 polyornithine/5 μg mL−1 laminin‐coated
dishes. Cells were fixed in 4% paraformaldehyde and immunostained for the
NPC marker Nestin (mouse anti‐Nestin; 1:500; EMD Millipore Corporation,
Billerica, MA) and mouse anti‐Nestin (1:500, EMD Millipore Corporation,
Billerica, MA).
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Exposure of hESC‐Derived NPCs to AuNPs: hESCs‐derived NPCs were
cultured on fibronectin‐coated six‐well dishes in N2/FGF2 medium and
chronically exposed to vehicle or the different sized AuNPs for 72 h, at which
time cells were fixed and immunostained for Nestin and the DNA marker
DAPI. The total number of Nestin‐positive cells and DAPI‐stained nuclei were
counted in five fields per well in three separate experiments, by an observer
blind to the experimental conditions. The number of cells harboring pyknotic
nuclei was also calculated. Total numbers were expressed as a percentage of
the total number of cells, as evaluated by DAPI or Hoescht staining.
Neuronal

Differentiation

of

hESC‐Derived

NPCs:

Neuronal

differentiation of NPCs derived from control and AuNP‐exposed hESCs was
achieved as previously described.(189, 193) NPCs were cultured on
polyornithine/laminin‐coated 12‐well dishes at a 5105 cells cm −2 density in
N2 medium supplemented with 10 ng mL−1 brain‐derived neurotrophic factor
(BDNF), 10 ng mL−1 glial cell‐derived neurotrophic factor (GDNF), 10 ng
mL−1insulin‐like growth factor (IGF) (all factors from Peprotech, Rocky Hill,
NJ), 200 ng mL−1ascorbic acid (Sigma‐Aldrich, St Louis, MO), and 100 ng
mL−1 cAMP (Sigma‐Aldrich, St Louis, MO). Cells were fixed and stained for the
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neuronal marker microtubule‐associated protein 2 (MAP2) (mouse antibody;
1:500, EMD Millipore Corporation, Billerica, MA).
Morphological Analysis of MAP2‐Positive Cells: Determination of
neuritic complexity of MAP2‐positive cells derived from control and AuNP‐
exposed hESCs was performed using Sholl analysis, as previously
described.(189) Neurons were randomly selected for which neurites could
be clearly identified and distinguished from neighboring cells. For each
experimental condition, analysis of 18–27 neurons were performed blindly
to well treatment. For each neuron examined, the average sum of crossings,
the average maximal neuritic distance, and the average total number of
branchings were recorded.
Antibodies

and

Immunofluorescence

Procedures:

Immuno-

fluorescence staining was performed as previously described.(194) Following
fixation in 4% paraformaldehyde, cells were rinsed in PBS, blocked in 3%
donkey serum (Sigma‐Aldrich, St Louis, MO) in 0.3% Triton‐X‐100 (NDST3%),
and incubated overnight at 4 °C with the primary antibodies diluted in
NDST1%. After several rinses in NDST1%, cells were incubated for 2 h in the
dark with secondary anti‐mouse antibodies conjugated to Alexa 488 (1:1000,
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Life Technologies Corporation, Carlsbad, CA). Following rinses, cells were
stained with the nuclear marker DAPI (Sigma‐Aldrich, St Louis, MO).
Specificity of the immunostainings was assessed by replacing the primary
antibodies with normal serum, and by omitting one immunoreagent of the
immunostaining protocol.
Statistical Analysis: Statistical significance between experimental
groups was determined by Student's t‐test or one‐way analysis of variance
(ANOVA) followed by a post hoc Holm–Sidak test when F value was
significant, or Kruskal–Wallis one‐way ANOVA on ranks followed by Dunn's
test using the SigmaPlot 12 software (SYSTAT Software Inc., San Jose, CA).
Statistical significance was defined at p ≤ 0.05. Data are expressed as the
mean ± SEM.
Immunoprecipitation

Based

Colometric

Assays:

Global

DNA

methylation status of exposed and control hESCs were determined using
MethylFlash Methylated DNA Quantification Kit (Catalogue No. P‐1034) and
MethylFlash Hydroxymethylated DNA Quantification Kit (Catalogue No. P‐
1036) from Epigentek. Briefly, 200 ng of DNA was bound to the bottom of
pretreated wells and 5 hmC DNA was detected using sequential treatment

106

with capture antibody and detection antibody. The final colorimetric signal
was normalized to the standard input DNA to estimate the overall
methylation percentage.
5.3 Results
5.3.1 AuNP characterization
All nanoparticles were synthesized following the methods described
previously. The sizes of as synthesized AuNPs were confirmed with TEM and
DLS (Figure 5.1). The diameters of AuNP core were determined to be 1.5 ±
0.1 nm for AuNP1.5, 4.2 ± 0.5 nm for AuNP4, and 13.6 ± 0.4 nm for AuNP14,
respectively (Figure 5.1 A). In order to prevent aggregation of AuNPs after
addition of culture medium, AuNPs were incubated with bovine serum
albumin (BSA) prior to the addition as BSA has been proved to be effective in
restraining nanoparticle aggregation.(33, 195) An increase in particle
hydrodynamic size of 4-6 nm was observed for AuNP4 and AuNP14 (Figure
5.1 C), which indicates the formation of protein corona. The core size of both
AuNP4 and AuNP14 remained unchanged according to UV-Vis spectrum,
which shows no shift of absorption peak after incubating with BSA. (Results
now included here).
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Figure 5-1 A) TEM images of AuNPs of average core diameters 1.5, 4, and 14
nm; B) DLS measurements of AuNP1.5, AuNP4, and AuNP14 in deionized
water; and C) AuNP4 and AuNP14after incubated with BSA in PBS buffer for
24 hours.
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5.3.2 AuNP size effect on hESC viability
To identify the potential AuNP toxicity, hESC were exposed to 10 μg
mL-1 AuNPs, largely above the nontoxic range(37) for 24 hours. No
remarkable differences in the growth and morphology of hESC colonies were
observed with exposure of AuNP4 and AuNP14 at the end of the experiment
compared to control cultures. In contrast, cells treated with AuNP1.5
exhibited loss of cohesiveness, rounding up, and detachment, suggesting
ongoing cell death, shown as Figure 5.2 A. Similar time-course and severity
of AuNP1.5-induced cell loss were observed when hESCs were cultured on
gelatin-coated plates instead of MEFs, suggesting a direct toxic effect of
AuNP1.5 on hESCs (data not shown). Trypan blue assays, which stain dead
cells, at the end of the 24 h treatment revealed statistically significant
differences in the viability of hESCs between the different experimental
groups (p< 0.001) (Figure 5.2 B). Thus, whereas no change in viability was
observed among control, AuNP4- (p= 0.79), and AuNP14- (p= 0.89) treated
cultures, a statistically significant 88% decrease in the number of viable
hESCs was observed following treatment with AuNP1.5 (p< 0.001).
Assessment of hESC viability using the MTT viability assay, a measure of
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mitochondrial function, provided comparable results with a statistically
significant 85% decrease (p= 0.028) in cell viability in AuNP1.5-treated hESCs
compared to controls (Figure 5.2 C).

Figure 5-2 Exposure of hESC to AuNPs. A) WA09 hESC cell colonies on MEF
feeder layer following 24 h exposure to vehicle, or 10 μg mL−1 of AuNP1.5,
AuNP4, and AuNP14. Only colonies exposed to AuNP1.5 exhibited altered
morphology suggestive of cell death. Arrows indicate MEFs with visible
intracellular uptake of AuNPs in the case of AuNP4 and AuNP14. AuNP1.5
was too small to be seen. The scale bar is 160 μm in the bright field
microscopic images; B) Cell viability analysis of hESCs exposed for 24 h to 10
μg mL−1 of the different sized AuNPs using Trypan blue assay; C)
Measurement of mitochondrial activity in hESCs exposed for 24 h to 10 μg
mL−1 of the different sized AuNPs by the MTT assay.

In order to determine the dosage dependent toxicity of AuNP1.5,
hESCs were treated for 4 d with six different sublethal concentrations
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ranging from 0.001 to 10 μg mL−1. The Trypan blue exclusion assay revealed
an IC50 value (the concentration necessary to kill 50% of the cells) of 1.45 μg
mL−1 in this 4 d exposure experiment.
5.3.3 AuNP cell uptake by hESC
Cells are known to uptake nanoparticles mainly through endocytosis,
and this process is dependent upon the size, shape, and surface chemistry of
nanoparticles.(150, 163) As shown in Figure 5.2 A, intracellular accumulation
of AuNP4 and AuNP14 could clearly be detected by optical microscopy in
cultures of hESCs grown on MEFs after a 24 h exposure to 10 μg mL −1
concentration. Using DAPI staining to visualize the differences in nuclear
chromatin patterns that exist between MEFs and hESCs,(196, 197) we
observed that the nuclei of AuNP-positive cells displayed the bright
fluorescent heterochromatin foci, characteristic of proliferating and
senescent MEFs(197) (Figure 5.3 A). In MEFs, AuNPs appeared as black dots
that distributed throughout the cellular cytoplasm, preferentially
aggregating around the nucleus (Figure 5.3 B, 5.3 C). Because no clear uptake
of AuNP1.5 could be observed in the cultures, we used the GoldEnhanceTM
(Nanoprobes) amplification method which revealed the presence of labeled
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MEFs (Figure 5.3 D). In contrast, no accumulation of the AuNP1.5 observed
in hESCs, even after the GoldEnhanceTM treatment (data not shown). Based
on this result, we observed no visible intracellular entry of AuNP1.5 at
sublethal dosages.

Figure 5-3 Uptake of AuNPs by MEFs but not hESCs. A) Cell cultures stained
with the nuclear marker DAPI showing the bright heterochromatin foci
characteristic of MEFs (long arrows), which allow to distinguish them from
hESCs(arrowheads). Uptake of B) AuNP4 and C) AuNP14 was clearly visible in
MEFs, but not in hESC colonies (region marked by *) delineated by dotted
lines. D) Uptake of AuNP1.5 by MEFs was only visible following intensification
with GoldEnhanceTM (arrows). The scale bar length in (D) valid for (A)–(C) is
50 μm.
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5.3.4 AuNP effect on hESC pluripotency and differentiation
The pluripotency of hESCs enables them to differentiate into multiple
tissue types. Here we determined the effects of AuNP exposure towards the
capabilities of hESCs to generate ectodermal, mesodermal, and endodermal
derivatives. To this end, we passively differentiated hESC-derived embryoid
bodies (EBs) for 2 weeks in basic fibroblast growth factor (bFGF)-free stem
cell medium, while exposing them to either AuNPs or vehicle. The
concentration for AuNP4 and AuNP14 was 10 µg mL-1 while a sublethal
dosage of 0.6 µg mL-1 was used for AuNP1.5. As shown in Figure 5.4,
quantification of marker mRNAs indicated that there were no statistically
significant differences in the expression levels of NCAM (Figure 5.4 A),
NESTIN (Figure 5.4 B), BRACHYURY (Figure 5.4 C), PITX2 (Figure 5.4 D), LEFTY
(Figure 5.4 E), NODAL (Figure 5.4 F) and AFP (Figure 5.4 G). These gene
expression results suggest that, at the concentrations tested, exposure to
AuNPs did not markedly alter the in vitro differentiation potentials of hESCs.
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Figure 5- 4 Characterization of the effects that 14 d exposure to AuNP1.5 (0.6
μg mL−1), AuNP4 (10 μg mL−1), and AuNP14 (10 μg mL−1) has on the
capability of hESCs to passively differentiate into cells of the three germ
layers.
To examine the effects of exposure to various sized AuNP on the
neural differentiation of hESCs, we generated EBs and maintained them
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throughout the entire neural differentiation protocol (19 days) in presence
of vehicle or 10 μg mL-1 AuNP1.5, AuNP4, and AuNP14. The presence of
AuNP4 and AuNP14 in the medium did not prevent the formation of EBs,
which appeared morphologically similar to those generated from vehicleexposed EBs (Figure 5.5). In contrast, AuNP1.5-exposed hESCs did not form
EBs but rather rapidly disintegrated into single cells within 48 hours of
treatment, so that by day 3, no EBs survived (Figure 5.5). Therefore,
following experiments were carried out using a 0.6 μg mL -1 (EC30)
concentration for AuNP1.5, which allowed the formation of EBs. During
neural differentiation, both control and AuNP1.5-treated EBs were able to
generate neural rosettes (Figure 5.5). However, the neural rosettes formed
by AuNP1.5-exposed EBs were small, exhibiting a dark aspect (Figure 5.5),
and did not survive. The data suggest that even at sublethal dosage AuNP1.5
causes adverse effect on neuronal differentiation of hESCs.
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Figure 5 5 Formation of embryoid bodies and neural rosettes by control and
AuNP-exposed hESCs.

5.4 Discussions
Our data show that thiolate-capped AuNP4 and citrate-capped
AuNP14 are nontoxic to hESCs and do not affect hESC pluripotency or
neuronal differentiation into NPCs. Our data also show that thiolate-capped
AuNP1.5 is toxic to hESCs with an IC50 value measured during 4-day exposure
of 1.45 μg mL−1 (or 0.0706 M). At first glance, our results appear to be
consistent with other reports, in particular, the one on size-dependent
cytotoxicity of AuNPs.(198) The paper showed that AuNPs of 15 nm in size
are nontoxic while AuNPs of 1-2 nm in size are highly toxic to a variety of cell
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lines (SK-Mel-28 human melanoma, HeLa human cervix carcinoma, L929
mouse fibroblasts, and J774A1 mouse macrophages). However, a closer
examination points to major differences between the current study and the
previous studies. In a previous report, Au55 cluster with a diameter of 1.4 nm
capped by triphenylphosphine monosulfonate (TPPMS), denoted as
Au1.4MS, was found highly toxic to a number of human cancer and healthy
cell lines.(168) The IC50 value of Au55 was determined to be 0.62 M for
fibroblast cells measured at 24 h.(168) Au1.4MS was found to cause necrosis
by oxidative stress and mitochondrial damage.(173) A subsequent study
showed that when the phosphine ligand was replaced with a thiol ligand,
glutathione (GSH), Au55 cytotoxicity was greatly reduced.(173) The authors
attributed the toxicity of Au1.4MS to weak phosphine/metal binding that
allows surface gold atoms to interact directly with biological targets.
However, in our study, we found that even thiolate-capped Au55 is toxic to
MEFs and hESCs. In addition, the IC50 of hESCs is much less than the values of
fibroblast and cancer cells, which indicates that hESCs are more sensitive to
nanoparticle perturbations. The other major finding of this study is that
AuNP1.5 imposes adverse effects on hESC survival and neuronal
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differentiation without obvious intracellular uptake. This observation argues
for the AuNP1.5 interactions with the cell membrane as the cause of its
cytotoxicity.
In the literature, several mechanisms of AuNP cytotoxicity have been
proposed. One is the size match between Au55 and the DNA major groove
and Au55 irreversible coordination to DNA.(168) The second is the induction
of reactive oxygen species (ROS) formation due to Au55’s electronic/catalytic
properties (it excites O2 but is not oxidized itself). Transition metals such as
gold are capable of one-electron reduction of oxygen and production of
reactive oxygen species such as superoxide radicals, hydrogen peroxide, and
hydroxyl radicals, which then can cause oxidation of biomolecules.(199, 200)
The third mechanism is Au55’s capability to block membrane ion channel.(201)
In another study of AuNP surface functionalities on zebrafish embryonic
gene expression, 2-mercaptoethanesulfonic acid (MES)-capped 1.5 nm
AuNPs were found to affect ion channel transport mechanism signaled by
misregulated gene expression.(202) It has been suggested that such gold
clusters could be used for cancer treatment if toxicity to normal cells can be
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controlled.(155, 203) Our data are more consistent with the third mechanism
of AuNP1.5 interfering with membrane ion channel functions.
5.5 Conclusions
This work described effect of AuNPs with core size of 1.5, 4, and 14 nm
on hESC viability, cell uptake, pluripotency, and differentiations. AuNPs were
used as model nanoparticles due to their versatile surface chemistry, ease of
imaging, and tunability for targeted drug/imaging agent delivery. We found
that hESC colonies exposed to 1.5 nm MSA-capped AuNPs exhibited loss of
cohesiveness, rounding up, and detachment suggesting ongoing cell death.
The hESCs exposed to 1.5 nm AuNPs did not form EBs but rather rapidly
disintegrated into single cells within 48 h of treatment. Cell death caused by
1.5 nm AuNPs also occurred in the treatment with hESC-derived neural
precursor/progenitor cells. None of the other nanoparticles exhibited
toxicity to the hSECs or their derivatives in experiments lasting as long as 19d.
In contrast to some reports, we found that Au55 capped by the strongly
binding thiolate could still be toxic to cells. Our data suggest that hESC uptake
of nanoparticles may be different from other cell types as we did not observe
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significant amount of AuNPs inside the hESCs while AuNPs were clearly
present inside the MEF feeder cells.
CHAPTER 6 CONCLUSIONS
This dissertation described a novel way to achieve targeted delivery of
a type of neural therapeutic drug, which could bypass blood-brain barrier,
without introducing noticeable side effect. The method is obtained by
engineering the surface of gold nanoparticles followed by conjugation with
drug and targeting protein. The stability of the nanoconjugates has been
characterized, potency was tested on established animal model and recovery
was detected. The releasing kinetics was also undergoing further research.
This dissertation also described a nontoxic way to increase solubility
and bio-accessibility of anti-cancer drug by conjugating the drug with
surface-modified gold nanoparticle. The decrease of tumor size was
observed after administration of the nanoconjugate, and the biodistribution
study was conducted.
In conclusion, a careful engineering of the gold nanoparticle gives a
good opportunity to improve performance of neural therapeutic drugs and
anti-cancer drugs after a designed chemical conjugation. Especially given
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that gold nanoparticle with size larger than 2 nm in diameter is nontoxic,
which is also discussed in this dissertation. The engineering of gold
nanoparticle to achieve biocompatible nanoconjugates has a great potential
in bio-medical area.
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ABSTRACT
ENGINEERING OF GOLD NANOPARTICLES FOR TARGETED DRUG DELIVERY
by
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Degree: Doctor of Philosophy
Due to their ease of synthesis, versatile surface chemistry, ease of
imaging, and biocompatibility, gold nanoparticles (AuNPs) are employed as
drug delivery devices in the treatment of respiratory problems associated
with spinal cord injury (SCI). We have developed a method for the synthesis
of a tripartite nanoconjugate comprised of an AuNP drug carrier chemically
conjugated to a transporter protein (wheat germ agglutinin coupled to
horseradish peroxidase or WGA-HRP) and to potent SCI drugs. The
therapeutic efficacy and biodistribution were studied in a validated animal
model. Our results show that a single administration of the nanoconjugate
improved diaphragmatic activity at a much lower dosage than the effective

150

systemic drug dosage and restored the respiratory drive. The effects lasted
for 4 weeks. A biodistribution study using inductively coupled plasma mass
spectrometry on the same animal model shows that the nanoconjugate was
successful in targeting the respiratory neurons in the medulla by detecting
the presence of gold in the medulla and spinal cord. The AuNPs are also
applied in triple negative breast cancer treatment. By conjugating the
surface modified AuNPs with a non-soluble drug, the solubility has been
increased and introduced cancer cell death after administration. The
nanoconjugate structure was determined by UV-vis spectroscopy,
transmission

electron

microscopy,

dynamic

thermogravimetric analysis, and mass spectrometry.

light

scattering,
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